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Malaria remains a disease of global health concern, as thousands of people fall victim to it 
annually. Despite the continuous development of new malaria chemotherapies, the parasite 
has adapted and mutated, conferring multi-drug resistant strains. The constant emergence of 
drug-resistant strains of malaria and the decrease in efficacy of most front-line treatments 
calls for the urgent development of new antimalarial chemotherapeutic drugs. It is of great 
importance to develop compounds that target resistant strains of malaria.  Chloroquine is one 
of the most significantly studied antimalarials to date and its derivatives have been mainstays 
in malaria treatment. It has also been established that carbon monoxide (CO) is able to 
prevent Experimental Cerebral Malaria (ECM) (a severe form of malaria) through the 
prevention of haemoglobin oxidation. This study investigated the synthesis, characterization 
and biological evaluation as antiplasmodial agents of two new quinoline-1,2,4-triazole ligands 
and their respective Mn(I) and Re(I) tricarbonyl complexes. The two ligands differ in the 
presence of an extended amino-propyl chain conjugated to the quinoline scaffold, which has 
proven to confer greater antimalarial activity. Furthermore, the complexes were evaluated 
for their potential as photoCORMs (photo-induced Carbon Monoxide Releasing Molecules) 
and the CO-releasing effects on the antiplasmodial activity were evaluated.  
Two manganese tricarbonyl complexes (Mn-1 and Mn-2: contains amino-propyl chain) were 
evaluated for their CO-releasing properties upon photoexcitation with UV light at 365 nm. 
Both complexes release CO upon photoexcitation in DCM, DMSO/PBS and DMSO/growth 
medium solutions. The rate of CO-release is medium-dependent and the Mn-1 complex 
releases CO faster than the Mn-2 complex.  
The ligands and metal complexes were evaluated for their in vitro antiplasmodial activity 
against the NF54-chloroquine-sensitive and the K1-chloroquine-resistant strains of 
Plasmodium falciparum (P. falciparum). All tested compounds show good antiplasmodial 
activity with 𝐼𝐶50 values in the low micromolar range. The manganese and rhenium analogues 
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exhibit similar antiplasmodial activities, with 𝐼𝐶50 values of 3.81 μM and 4.61 μM in the CQ-
sensitive strain respectively. Both complexes retain their activity in the CQ-resistant strain 
with resistance indices of 1. The ligand containing the amino-propyl chain (L2) exhibits the 
greatest antiplasmodial activity with 𝐼𝐶50 values of 0.33 μM and 0.69 μM in the CQ-sensitive 
and -resistant strains respectively. The manganese complex thereof (Mn-2) has 𝐼𝐶50 values of 
0.54 μM and 1.16 μM in the CQ-sensitive and -resistant strains respectively. 
The antiplasmodial activity of the manganese complexes Mn-1 and Mn-2 increases 7- and 3-
fold respectively upon photoexcitation at 365 nm in the K1-CQ-resistant strain. The increase 
in antimalarial activity exhibited upon light-induced CO-release presents a promising 
mechanism of combating drug-resistant P. falciparum. Mechanistic studies of these 
compounds indicate that they potentially work via β-hematin inhibition, with the metal 
complexes being greater inhibitors than CQ. Upon photo-induced CO-release, the β-hematin 
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ACT    Artemisinin Combination Therapy 
ATR     Attenuated total reflectance  
BCN    Bicyclo-[6.1.0]nonyne 
br      Broad  
CNR    Click and release 
COMb     Carboxy-myoglobin  
CORMs   Carbon Monoxide-Releasing Molecules 
CQ    Chloroquine  
CQDP    Chloroquine diphosphate 
CuAAC    Copper-catalyzed azide/alkyne cycloaddition 
d      doublet (NMR) 
DCM     Dichloromethane  
dd      doublet of doublets (NMR) 
Deoxy-Mb    Deoxy myoglobin  
DHFR    Dihydrofolate reductase 
DHPS    Dihydropteroate synthase 
DIPEA    N,N-Diisopropylethylamine 
DMF    Dimethyl formamide 
DMSO     Dimethylsulfoxide 
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ECM    Experimental cerebral malaria 
EI     Electron Impact 
eq.     Equivalent(s) 
EtOAc    Ethyl acetate 
fac    Facial 
FAQ    Fluoroamodiaquine 
FQ    Ferroquine 
FT-IR    Fourier transform infrared spectroscopy 
FV    Food vacuole 
HO    Heme oxygenase 
HPPK    Hydroxymethylpterin Pyrophosphokinase 
HSQC    Heteronuclear single quantum correlation 
Hz     Hertz 
ILCT     Intraligand charge transfer 
IR     Infrared 
J     Coupling constant 
Lit.      Literature 
m     Multiplet (NMR) 
m/z     Mass to charge ratio 
Mb     Myoglobin 
MB    Methylene Blue 
MDR    Multi drug resistant 
MeCN    Acetonitrile 
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MeOH    Methanol 
mer     Meridional 
MLCT    Metal-to-ligand charge tranfer 
MsCl    Methanesulfonyl chloride 
NADH    Nicotinamide adenine dinucleotide 
NMR    Nuclear magnetic resonan 
p    Pentet (NMR) 
PBS     Phosphate buffer saline 
pfCRT    Plasmodium falciparum Chloroquine Resistance Transporter 
photoCORMs   Photo-activated Carbon Monoxide-Releasing Molecules 
pLDH    Plasmodium lactate dehydrogenase 
q     quartet (NMR) 
RBC    Red blood cell 
ROS    Reactive Oxygen Species 
s     Singlet (NMR) 
SNAR    Nucleophilic Aromatic Substitution 
SOCl2    Thionyl chloride 
SP    Sulfadoxine-pyrimethamine 
t     triplet (NMR) 
THF     Tetrahydrofuran 
TPCPD    Tetraphenylcyclopentadienone 
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1.1. History and prevalence of malaria 
 
Malaria is a mosquito-borne infectious disease caused by a protozoan of the Plasmodium 
genus.1 The disease is proposed to date back to as early as 2700 BC,2 where there are several 
references made to its symptoms in ancient Mesopotamia clay tablets, Egyptian papyri, Indian 
writings and Greek texts.1 Malaria is thought to have arrived in Rome in the first century AD 
via the Nile River to the Mediterranean after which it reached Greece, England and Denmark.  
For the 2 000 years that followed, malaria flourished in Europe, as many fell victims to it.2  
The malaria parasite was first discovered in the blood of infected patients by Alphonse 
Laveran in 1880.3 The Italian neurophysiologist, Camillo Golgi later discovered in 1886 that 
there were at least two forms of the disease, the “tertian” and the “quartan” forms.4 The 
tertian form occurs in patients who have a fever every other day and the quartan form occurs 
when patients have a fever every third day. Golgi noticed that these two forms were 
accompanied by different numbers of new parasites.5 Ronald Ross was the first to discover 
that avian and human malaria uses mosquitoes as its vector.6  The sexual stage of the 
parasites’ life cycle was discovered by William MacCallum in 1897 whereas the transmission 
process was discovered in infected birds by Ronald Ross in 1898.1 Finally, the dormant stage 
of the parasites life cycle was discovered to take place in the liver by Wojciech Krotoski in 
1982.1  
Malaria has plagued the United States for decades but nowhere past or present has it taken 
a bigger toll than it has on Africa.2 Approximately 50% of the world’s population is at risk of 
contracting the disease.7 According to the latest World Malaria Report, there were 219 million 
malaria cases and 435 000 related deaths in 2017.8 Most of these deaths occur in pregnant 
woman and children under the age of 5, majority of who die within 72 hours of their 
symptoms.9,10 There are several species of malaria parasites, but only five cause infection in 
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humans, these are: P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi, with P. 
falciparum being responsible for the majority of the deaths.11  
 
1.2. Biology of the Plasmodium parasite 
 
The life cycle of the Plasmodium parasite shown in Figure 1.1 illustrates that the parasite 
requires two hosts: a mosquito (the vector) and a human host.12 Sexual reproduction occurs 














The parasitic life cycle begins when an infected female Anopheles mosquito takes a blood 
meal from the human host.13 The sporozoites from the parasite are injected into the humans’ 
bloodstream via the mosquitos’ saliva. These sporozoites enter the liver, where they mature 
and multiply, eventually causing the cells to rupture releasing merozoites back into the 
Figure 1.1. Life cycle of the Plasmodium parasite.12 
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bloodstream.14 These merozoites invade the red blood cells (RBCs) where they undergo 
asexual reproduction, forming either schizonts or trophozoites. Each schizont then divides, 
once again forming merozoites that are released to invade erythrocytes.12 Several merozoites 
mature into gametocytes (both male and female) at which point a mosquito can once again 
take a blood meal, taking up the Plasmodium gametes, initiating the sexual reproductive cycle 
in the mosquito.15 The female and male gametes fuse and are taken up into the midgut where 
they mature and the life cycle repeats itself.12  
Parasitic pathogenesis only occurs during the asexual blood stage of the life cycle.11 During 
this stage, the parasite consumes and degrades the haemoglobin found in the RBCs.11,16 
Degradation occurs in an acidic food vacuole (FV) with pH range of 5.2-5.6.16 In the FV, the 
iron centre of haemoglobin undergoes oxidation to form Heme.17 At high enough 
concentrations, this heme is toxic to Plasmodium as it produces reactive oxygen species 
(ROS), as illustrated in Figure 1.2.18 ROS causes “lipid peroxidation”, a toxic process whereby 













Figure 1.2. Proposed mechanisms of free heme toxicity in the malaria parasite. Haemoglobin 
(Hb), food vacuole (FV), infected red blood cell (IRBC), Parasitophorous vacuolar membrane 
(PMV), reactive oxygen species (ROS). 
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Figure 1.3. Structure of hemozoin. 
To avoid susceptibility to lipid peroxidation and subsequent death, the parasite has evolved a 
detoxification method, during which free heme is polymerized into a form of β-haematin 
known as hemozoin.19 Hemozoin is a highly insoluble crystalline molecule that forms in the 
digestive vacuole of the parasite.20 There is evidence indicating that hemozoin (Figure 1.3) is 
a polymeric dimer of heme.21 The mechanism of hemozoin formation is unclear but has been 
thoroughly debated over the years.11,16 Some of these proposed mechanisms include protein-
mediated hemozoin formation,22,23 lipid-mediated hemozoin formation,24 
biomineralization,25 or biocrystallization.26 Hemozoin can also spontaneously be synthesized 
by incubating monomeric hematin (at 37 ℃ and pH 4.8) in the absence of parasitic material 
to form the synthetic form of hemozoin known as 𝛽-hematin.18 Hemozoin resembles β-
haematin chemically, spectroscopically and crystallographically which serves as great 










1.3.  Treatment 
 
Quinine (Figure 1.4) was one of the first drugs used to treat malaria, going down in history as 
one of the first chemical compounds to successfully treat an infectious disease.27 Quinine 
naturally occurs in the bark of Cinchona trees and was isolated in 1820.28  Studies carried out 
in the years 1866-1868 resulted in the discovery of other cinchona alkaloids such as quinidine, 
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cinchonine and cinchonidine which are also effective antimalarials. Quinine was primarily 






Guttmann et al. reported the antimalarial properties of a synthetic thiazine dye, methylene 
blue (MB) in 1891,29 and it was the first synthetic drug used to treat malaria.30 Its identification 
as an antimalarial led to the discovery of 8-aminoquinolines.31 Subsequently, methylene blue 
analogues were synthesized in which the methyl group was replaced with a simple side 
chain.32 These analogues exhibit increased antimalarial activity, leading to the belief that 
these side chains elicit favourable activities. From here, pamaquine (Figure 1.5) was 
discovered in the 1920s and was first used in 1926, but was later found to exhibit high 
toxicity.32 Primaquine (Figure 1.5) was then synthesized as a less toxic derivative and is used 











Figure 1.4. Structure of Quinine. 
Figure 1.5. Structure of two methylene blue analogues (pamaquine and primaquine) used 
as antimalarial agents 
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The antimalarial activity and reduced toxicity of the primaquine led to the application of side 
chains in several other heterocycles, leading to the discovery of chloroquine (CQ)                 








Before the emergence of resistance, chloroquine was the ideal antimalarial drug, displaying 
high therapeutic activity, low toxicity and low cost.34 As previously mentioned in Section 1.2, 
the malaria parasite detoxifies free heme via polymerization into hemozoin. In CQ-susceptible 
strains of malaria, CQ can prevent the detoxification process. Drugs like quinine and 
chloroquine inhibit hematin polymerization and the accumulation of free heme, rendering 
these drugs toxic to the parasite.35 Chloroquine also inhibits β-haematin synthesis at 
physiological temperatures.36,37  
 
1.3.1. Quinoline and non-quinoline drugs 
 
Over the many years that malaria has been a global health problem, many antimalarial 
chemotherapeutics have been synthesized. These include compounds based on the well-
known quinoline scaffold of chloroquine as well as compounds based on different scaffolds. 
Among the non-quinoline containing antimalarials are the artemisinin’s which are used in the 
current antimalarial regime. Currently, the frontline treatment for malaria is artemisinin 
combination therapy (ACT).38 ACT combines artemisinin or an artemisinin derivative and a 
drug from a different class such as mefloquine, piperaquine and lumefantrine.39,40 Professor 
Youyou Tu won the 2015 Nobel Prize in Physiology or Medicine for her vital role in the 
Figure 1.6. Structure of the antimalarial chloroquine. 
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discovery of artemisinin.41 
1.3.1.1. Quinoline-based antimalarials 
 
The quinoline scaffold has prevailed over the years in pharmacologically synthesized 
compounds as well as in nature.37   This scaffold is historically considered to be one of the 
most vital in antimalarial drug discovery, with CQ dominating these groups of compounds. 
Other quinoline derivatives include amodiaquine, piperaquine, primaquine, quinine and 
mefloquine, some of which are shown in Figure 1.7.42 None of these alternate drugs have 
shown any pharmacological superiority over chloroquine and therefore the search for a more 
or as effective drug continues.43 CQ  gains its antimalarial properties through π-π stacking, 
allowing the drug to prevent hemozoin formation.44 This π-π stacking occurs through 
interaction of the 4-aminoquinoline scaffold with the heme group or by the drug docking into 
the grooves of hemozoin, preventing crystal growth.42 The toxic hematins are able to leave 














CQ is administered orally to patients in the form of CQ-phosphate tablets and is a blood 
schizonticidal drug. Blood schizonticidal drugs only act efficiently during the RBC stage of the 
parasite's life cycle,45 losing its efficacy once the parasite progresses into the liver stage. CQ 
can be divided into three parts as labelled in Figure 1.8.43 The tertiary amine found on ring B 
Figure 1.7. Structures of quinoline derivatives. 
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is essential for the uptake and accumulation of the drug in the parasitic food vacuole.43, 46 The 
aromatic and quinine rings A and B are essential for π-π stacking of the molecule in the heme 
and any alteration to the Cl at position 7 has shown to render the compound less potent.43 
The π-π stacking allows the drug to intercalate between the polymeric crystal packing in the 
acidic food vacuole of the parasite, forming a dimeric hematin complex and therefore 









CQ is a weak base with pKa of 8.1 (quinoline nitrogen) and 10.2 (diethylamine side-chain 
nitrogen), it enters into the acidic parasitic FV (pH of 5-5.2) in its unprotonated form.45 
Uncharged CQ is membrane permeable and can, therefore, easily diffuse into the FV.48 When 
entering into the FV, chloroquine becomes protonated, a form which is not membrane 
permeable resulting in the accumulation of the drug in the FV.49 CQ  inhibits the 
polymerization of free heme into hemozoin, increasing intracellular heme.50 
The development of new 4-aminoquinoline derivatives is a valid strategy for malaria 
treatment, due to the promising antimalarial properties exhibited by chloroquine and its 
derivatives.43,51 Amodiaquine (Figure 1.7) is one such derivative, but due to side effects like 
hepatoxicity and agranulocytosis, its clinical use was restricted.52 This led to the synthesis of 
fluoroamodiaquine (Figure  1.9). O’Neill et al. demonstrated that fluoroamodiaquine (FAQ) 
retains the antimalarial activity observed for amodiaquine but does not exhibit the toxic side 
effects.53  
Figure 1.8. Labelled structure of CQ.43 
  








Stocks et al. generated a series of short-chain CQ derivatives, shown in Figure 1.10.54 The 
derivative containing the tert-butyl terminal amino group in the side-chain (d) was the most 
active. This derivative showed a 4- and 20-fold increase in antimalarial activity against the 








Madrid et al. synthesized a library of chloroquine derivatives in which the diethylamino side-
chain was replaced with bulkier groups as shown in Figure 1.11.55  The 𝐼𝐶50 values of the 
synthesized compounds show superior antimalarial activity in two CQ-resistant strains (W2 
and Dd2) compared to CQ. The derivative containing the bromobenzaldehyde moiety in the 
R2 position and a propyl chain in the R1 position exhibited the greatest antimalarial activity 
with an 𝐼𝐶50 value of 11 nm compared to 23 nm for CQ. 
 
Figure 1.9. Structure of fluoroamodiaquine. 
Figure 1.10. CQ derivatives synthesised by Stock et al.54  
  











Sunduru et al. synthesized a series of thiourea, thiazolidinedione and thioparabanic acid 
derivatives of 4-aminoquinolines.56 These compounds were evaluated for their in vitro 
antiplasmodial activity and the thiourea derivative shown in Figure 1.12 exhibited the highest 
antiplasmodial activity. The thiourea derivative has an 𝐼𝐶50 value of 6.07 ng/mL against the 










Figure 1.11. CQ derivatives synthesised by Madrid et al.55  
Figure 1.12. Thiourea derivative which exhibits the highest antiplasmodial activity against CQ-
sensitive strain of P. falciparum.56 
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1.3.1.2. Non-quinoline based drugs 
 
Among the well-known non-quinoline antimalarials is artemisinin (Figure 1.13). Artemisinin 
was discovered by Chinese researches and exhibits high potency against CQ-sensitive strains 
of P.falciparum.57 The biological activity and complicated structure of artemisinin led to the 










The mechanism of action of artemisinin and its derivatives are different from quinoline-based 
drugs, as their structures differ vastly. Artemisinin contains an endoperoxide bridge and 
peroxides are known to produce reactive oxygen species.59 Inside the patristic FV, artemisinin 
interacts with free heme and the peroxide bridge is cleaved, producing ROS.60 Their exact 
mechanism of action is debated but it is proposed to occur through both a parasite-specific 
and non-specific mechanism.61   
Currently, the front-line treatment for malaria is artemisinin combination therapy (ACT). ACT 
increases the efficacy of the treatment by targeting more than one stage in the parasites life-
cycle, decreasing the probability of resistance.12 The artemisinin derivatives are the fastest 
acting compared to all other antimalarials.62 This class of drug also displays a wider range of 
antimalarial activity, acting at more than one stage of the parasite life cycle.63 Initially, it exerts 
its activity at the young ring stage and then prevents the maturation of the parasite into the 
more pathogenic stages.62,64  
Figure 1.13. Structure of artemisinin and two of its derivatives 
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Another class of non-quinoline antimalarial drugs is the antifolates and is comprised of sulfa 
drugs that can be subdivided into two classes: class I and class II antifolates. Antifolates target 
the folate metabolism in the malaria parasite (Figure 1.14), which is an important metabolic 
pathway in the parasite's survival.65 Class I antifolates inhibit dihydropteroate synthase 
(DHPS). Class II antifolates inhibit dihydrofolate reductase (DHFR).66 DHFR and DHPS inhibitors 
are used in combination in order to produce a synergistic outcome.67 Drugs belonging to class 
I include: sulfadoxine, sulfalene and dapsone. Those belonging to class II include: proguanil, 














The folate derivatives synthesized via the folate pathway are essential cellular cofactors and 
provide single carbon (C1) units that are used in the following metabolic pathways: 
methionine, purines and pyrimidine’s biosynthesis.68 These single carbon units are essential 
for  DNA replication and the initiation of protein synthesis in mitochondria.68 Thus, any drug 
that inhibits the various enzymes involved in this pathway can be exploited in the 
development of antimalarials.68 Pyrimethamine and cycloguanil (the active form of proguanil) 
Figure 1.14. Parasitic folate pathway, showing the principle enzymes and subtrates.62  
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targets the DHFR activity of the parasites bifunctional DHFR-thymidylate synthetase (TS) 
protein.69 The sulfa drugs affect the dihydropteroate synthetase (DHPS) activity of the 
bifunctional hydroxymethylpterin pyrophosphokinase (HPPK)-DHPS protein. Each of these 
antifolate drugs acts to competitively inhibit the parasites natural substrates.69  
 
1.4.  Drug resistance 
 
Despite the extensive resources and research that goes into the investigation of effective 
antimalarials, drug-resistant strains of malaria continue to triumph. The geographical map 
shown in Figure 1.15 illustrates that malaria is endemic in areas of America, Africa, Asia and 
Sub-Saharan Africa. Most of these regions are dominated by CQ or multi-drug resistant strains 














Figure 1.15. Geographical distribution of malaria obtained from the 2018 World Malaria 
Report.8 
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As previously mentioned in Section 1.3.1.1, CQ was widely used as the mainstay drug until 
the emergence of CQ-resistant strains of P. falciparum. This led to the use of antifolate 
combination SP (sulfadoxine-pyrimethamine) chemotherapy.70 Resistance to antifolate 
combination therapy subsequently led to the use of the current ACT frontline treatment.70 In 
2008 Dondorp et al. documented resistance to artesunate monotherapy in the P.falciparum 
species.71 The development of ACT resistance threatens the population as scientists fear that 
malaria may soon become untreatable.72 The progressive emergence of resistance to all 
synthesized antimalarials has resulted in the development of multi-drug resistant (MDR) 
strains of the parasite.73  
The mechanism by which the malaria parasite becomes resistant to antimalarials usually 
involves chromosomal mutations.74 CQ-resistance in P.falciparum is conferred by the 
mutation in the pfCRT (Plasmodium falciparum Chloroquine Resistance Transporter) gene.75 
Parasites with the mutated PfCRT gene has the ability to transport protonated CQ out of the 
cell, preventing the accumulation of the drug and resulting in CQ-resistance.76 Pyrimethamine 
and sulfa drug (PS, antifolates) resistance are attributed to mutations in the genes coding for 
the DHFR and DHPS enzymes.77  Resistance to antifolates can result from various mechanisms 
such as the overproduction of DHFR or the reduced ability of the antifolate to diffuse across 
the cell membrane.78 Artemisinin resistance differs from other antimalarials, as it is based on 
the enhanced entry of a larger number of young ring forms of the parasite into 
quiescence.79 Upon treatment with artemisinin, a large number of parasites become dormant 
and growth is resumed once artemisinin is no longer present.80 This enhanced ability to enter 
into quiescence is conferred by mutations in the Pfk13 gene.80  
 
1.5. Hybrid molecules 
 
Combination therapy is often used as an attempt to overcome resistance in diseases like 
malaria. Combination therapy involves the administration of two or more drugs at the same 
time to target more than one stage of a disease. The challenge with combination therapy is 
deciding the appropriate combinations of drugs and the correct doses of each drug. Instead 
of using two drugs in combination, molecular hybridization is a compelling alternative. 
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Molecular hybridization combines two pharmacologically active scaffolds into a single 
compound to increase the overall efficacy of the compound.81 The synthesis of hybrid 
molecules has become a promising method in the development of anti-cancer,82 anti-
tuberculosis,83 and antimalarial drugs.84 Due to the constant emergence of drug-resistant 
strains of malaria, it is essential to develop treatments that may eventually put an end to the 
prevalence of the deadly disease. The notion of hybrid molecules presents an opportunity to 
generate dual activity in antimalarials whereby two pharmacophores are introduced into a 
single molecule.85 This is done in hopes of synthesizing a compound with higher 
antiplasmodial activity than each of the individual drugs. 85 
 
1.5.1. Structure of hybrid molecules 
 
Hybrid molecules can be synthesized either via direct conjugation through a linker or by 
combining different haptophoric moieties of two or more drugs.81 Therefore, hybrid 
molecules can either be classified as 1) cleavable hybrids: two molecules directly linked or via 
spacers, which are hybrids that produce dual modes of action. 2) non-cleavable hybrids: two 
molecules connected via a linker that is enzymatically non-cleavable, these hybrids retain the 
pharmacological properties of both pharmacophores in a single compound. 3) Overlapping/ 
merged hybrids: obtained via the overlap of related structural moieties of two 
pharmacophores, these hybrids may or may not exhibit the biological properties of the parent 







 Figure 1.16. Representation of Cleavable, Non-cleavable and merged hybrids.82 
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1.5.2.  Quinoline-triazole hybrids 
 
Many studies report various antimalarial hybrids such as the artemisinin-based hybrids,86 
trioxaquines,84 and quinoline-triazoles.87 Triazoles have been reported to exhibit a range of 
biological activity such as antifungal, antibacterial, antitubercular and antimalarial.88,89 The 
quinoline-triazole hybrids have therefore been studied extensively and display high 
antiplasmodial activity against several strains of P.falciparum. 88, 90, 91  
Manohar et al. report a series of 4-aminoquinoline-1,2,3-triazole and 4-aminoquinoline-1,2,3 
triazole-1,3,5-triazine hybrid compounds.88 The two most active compounds are shown in  










The in vitro antimalarial activity of these hybrid molecules was determined against the D6-
CQ-sensitive and W2-CQ-resistant strains of P. falciparum. The 4-aminoquinoline-triazole 
hybrid containing the aryl scaffold (Figure 1.17, left) has an 𝐼𝐶50 value of 0.65 μM. The 4-
aminoquinoline-triazole-triazine hybrid on the right in Figure 1.17 has an 𝐼𝐶50 value of         
0.58 μM. This study also showed that 4-aminoquinoline –triazoles and –triazole-triazines 
displayed higher potency as the carbon spacer between the secondary amine and triazole ring 
increased from 1 to 3.  This trend was attributed to the increase in lipophilicity as the carbon 
Figure 1.17. Structures of most active 4- aminoquinoline-triazole and 4-aminoquinoline-
triazole-triazine hybrid molecules that were synthesised by Manohar et al.89 
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spacer was changed from 1 to 3.88 
Boechat et al. reports on a series of quinoline-1,2,3-triazole hybrid compounds with the 
general structure shown in Figure 1.18.90 The molecule shown on the right represents the 
hybrid that exhibits the highest activity with an 𝐼𝐶50 value of 1.4 μM. All 11 synthesized 
compounds displayed moderate to good activity and none showed toxicity to healthy monkey 










Pereira et al. synthesized a series of 4-aminoquinoline-1,2,3-triazole hybrids in which there 









Figure 1.18. General structures of 4- aminoquinoline-triazole hybrid molecules synthesised 
by Boechat et al. (left) and most active hybrid (right).91  
Figure 19. Structure of most active 4-aminoquinoline-triazole hybrid synthesized by Pereira 
et al.91  
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The 4-aminoquinoline-triazole hybrids were evaluated for their in vitro antiplasmodial activity 
against the W2-CQ-resistant strain of P. falciparum. The compounds displayed moderate 
antiplasmodial activity and low cytotoxicity when tested in Hep G2A16 cells. The hybrid 
shown in Figure 1.19 exhibited the highest antimalarial activity with an 𝐼𝐶50 value of 9.6 µM.
92 
 
1.6. Metals in Medicine  
 
The use of metals in medicine serves as a very important bridge between inorganic chemistry 
and the medical industry. Metallodrugs are used to detect and treat several diseases due to 
their biological applications on cellular living systems.93 Ancient history indicates that metal-
based drugs have been used as early as ancient Greece where silver was used to treat wounds 
and ulcers.94 The ancient Egyptians used copper to sterilize water and the medicinal use of 
gold in China dates all the way to 2500 BC.95  
In modern medicine, cisplatin (Figure 1.20) was one of the first completely inorganic 
compounds used. Cisplatin is a platinum-based drug that was first discovered by Rosenberg 
for its ability to inhibit cellular division in Escherichia coli.96 This led to the discovery of its 
antitumor properties in mice.97 The successful use of Cisplatin and other platinum-based 
anticancer drugs has prompted the investigation of metal-based compounds that could 







 Metal complexes have been reported to treat insulin resistance,99 inflammation,100  microbial 
infections,101 and parasitic diseases.102 The medicinal properties of metal compounds are 
 Figure 1.20. Structure of Cisplatin.  
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appealing as they provide a unique approach to drug synthesis. The addition of metal centers 
to organic drugs can also be used as a method of improving the efficacy of that organic drug.16 
The reactivity of the metal complex can be specified through metal and ligand choice. Metal-
based compounds are suitable for tropical parasitic disease treatment due to their excellent 




Sanchez-Delgado et al. were one of the first groups to synthesize transition metal (Rh and Ru) 
complexes with a CQ scaffold that exhibited comparable antimalarial activity to CQ.104 Initially 
a rhodium chloroquine derived complex [Rh(COD)(CQ)Cl] (Figure 1.21, left) was synthesized 
and tested for its antimalarial properties.104  The complex exhibited similar in vivo antimalarial 
activity to CQ. To increase the biological activity of the complex, ruthenium was used, and the 
ancillary ligand varied (Figure 1.21, middle and right). These RuII(η6-arene) chloroquine 












Figure 1.21. CQ derived metal complexes synthesized by Sanchez-Delgado et al.105 
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Scientists were encouraged by the enhanced activity of metal complexes leading to the 
development of other CQ-metal complexes. This includes the complexation of gold,105 
iridium,106 and platinum,107 to the organic CQ antimalarial. Due to the proven medical 
application of ferrocene complexes,108 ferroquine (FQ) was synthesized.16 FQ is a ferrocenyl 
derivative of CQ (Figure 1.22). FQ is active against both CQ-sensitive and -resistant strains of 
P. falciparum. A more active derivative of FQ is yet to be found, despite the many studies 
done on FQ and 120 of its derivatives.109 The ferrocene derivative is currently undergoing 
phase IIb clinical trials and is being tested in combination with artefenomel (an antiparasitic 
agent).110 It is quite evident that the modification of CQ with a metallic component such as 







The biological activity of FQ does not arise directly from the interaction of the organometallic 
moiety with parasitic proteins but can be afforded to two major aspects.40 The first is that, 
like CQ, FQ contains the 4-aminoquinoline moiety that allows the compound to accumulate 
in the parasite’s digestive vacuole.111  This prevents important metabolic processes and 
ultimately leads to parasitic death.111 The second mode of action involves the ferrocenyl 
substituent which generates hydroxyl (OH) radical species.112 The production of these radical 
species prevents the formation of merozoites (a form of the parasite that enters red blood 
cells during the parasite’s life-cycle).112  
Literature reports on many more metal-based antimalarials that makes use of various other 
transition metal centres like osmium, palladium, copper, nickel, cobalt, iridium and zinc.113 
Many of these complexes also exhibit higher antimalarial activity than the free uncomplexed 
ligand, like the palladium complexes reported by Chellan et al.114   
Figure 1.22. Structure of ferroquine.  
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1.7. Metal carbonyls 
 
Metal carbonyls play a crucial role in organometallic chemistry and have become popular in 
medicinal chemistry as carbon monoxide releasing molecules (CORMs) (see Section 1.8).115,116 
The carbonyl group bonds to the metal centre via σ bonding.117 Overlap of CO σ-orbitals with 
that of an empty d-orbital of the metal results in a strong σ-bond formation and delocalization 
of π-d electrons from the metal ion into an empty π*-orbital (anti-bonding) of the CO.117  This 
is called π-back-donation and results in a stronger M-C bond, but a weaker C-O bond.117 
Carbon monoxide (CO) is capable of forming complexes with both main group elements and 
transition metals, making it a versatile ligand. Some metal carbonyl complexes are also 
photoreactive, allowing them to undergo photo-induced reversible and non-reversible ligand 
exchanges and substitutions.117 For this reason, metal carbonyls can also function as benign 
transporters for CO, the basis of CORMs that will be discussed later.118  
 
1.7.1. Group 7 transition metal carbonyls  
1.7.1.1. Rhenium carbonyls 
 
Re(I) fac-tricarbonyl complexes that bear a low energy π* orbital have been found to be 
luminescent and biocompatible.119 Similar to the luminescent d6 Ir(III) and Ru(II) complexes, 
Re(I) tricarbonyl complexes are kinetically inert reducing the toxicity associated with heavy 
metal ion release.120 Re(I) carbonyl complexes have been used in photodynamic therapy in 
which non-toxic photosensitizers generate toxic species like ROS.121 This oxidative stress 
results in cell damage and can be applied in the treatment of cancer or infectious diseases 
like malaria.119 The rhenium tricarbonyl complex shown in Figure 1.23 contains a chloroquine-
derived ancillary ligand and was evaluated for its antiparasitic activity against the 
Trypanosoma brucei strain of malaria. The complex exhibited an 𝐼𝐶50 value of 0.9 µM and low 














Toro et al. synthesized a series of ferrocenyl and cyrhetrenyl benzimidazoles which were 
evaluated for their antimalarial activity against the 3D7-CQ-susceptible and W2-CQ-resistant 
strains of P.falciparum.123 The cyrhetrenyl complexes shown in Figure 1.24 exhibited higher 











1.7.1.2.  Manganese Carbonyls 
 
One of the well-known manganese carbonyls is manganese decacarbonyl, which has been 
extensively studied for its photo-dissociative properties,118 and was one of the first Mn 
carbonyls identified for its photo-dissociative properties.  
Simpson et al. Synthesized a series of five Mn(I) tricarbonyl complexes containing three azole 
ligands.124 The antiparasitic activity of the complexes were evaluated against Leishmania 
major and Trypanosoma brucei. Upon metalation, the Mn(I) tricarbonyl complexes exhibited 
low 𝐼𝐶50 values but high toxicity towards the mammalian cell lines 293T and J774. The metal  
Figure 1.23. Chloroquine-containing rhenium tricarbonyl. 
Figure 1.24. Cyrhetrenyl benzimidazoles synthesized by Toro et al.123 
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complex shown in Figure 1.25 showed the highest potency against Trypanosoma brucei with 















Minimum research has gone into the biological properties of manganese carbonyls as 
complexes. These complexes have more widely been studied as Carbon Monoxide-Releasing 
Molecules (CORMs) due to their dissociative properties.  
 
1.7.2. Carbon monoxide-Releasing molecules (CORMs) 
 
The use of metal carbonyls as biological agents has become popular in medicinal chemistry in 
the form of carbon monoxide releasing molecules (CORMs). CO-release from CORMs is 
initiated by external stimuli such as hydrolysis or solvolysis,125  enzymes,126 pH changes,127 
temperature,128 and light.129 CORMs mainly consist of transition metal carbonyls but non-
metallic CORMs have been reported in the literature.130,131 The CO-release rates and 
toxicological profiles of many organic CORMs were unfavourable and thus further studies 
were not performed.132  
 
 
Figure 1.25. Mn(I) tricarbonyl complex that exhibits good antiparasitic activity.  
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1.7.2.1. Carbon monoxide as a therapeutic agent 
 
CO is largely associated with carbon monoxide poisoning due to its high affinity for 
hemoglobin,133 and thus has a toxic effect on the oxygen metabolism.134  Although toxic at 
high concentrations, CO is also endogenously produced in minuscule amounts in mammalian 
cells under stress conditions and serves as a molecular messenger.135 Mammalian cells 
produce CO via the heme degradation process shown in Figure 1.26. During this process, 
heme oxygenase (HO) degrades heme into biliverdin, carbon monoxide and of Fe2+.136 Heme 
oxygenase’s consist of HO-1, HO-2 and HO-3. HO-1 is induced during stress, HO-2 is a 



















CO plays an essential role in metabolic processes such as inflammation,137 apoptosis,138 
vasodilation,139and in the inhibition of platelet accumulation.140 In addition to the therapeutic 
effects displayed by the gasotransmitter (a gaseous compound with a biochemical function), 
the application of CO extends much further. CO has received significant acknowledgment in 
Figure 1.26. Heme (left) and the degradation process of heme to bilirubin (right).138 
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the medical field for its application as an anticancer agent,116 antimicrobial properties,141 
antimalarial,142 and its successful use in organ transplants.143-144 CO also exhibits 
cytoprotective properties against certain reactive oxygen species that cause oxidative stress 
in cells.134 For these reasons, the use of CO as a therapeutic agent has gained momentum for 
its potential applications at non-toxic concentrations.125 The mechanism of action by which 
CO works to treat the aforementioned illnesses varies but is not fully understood for either of 
them. The mechanism of CO as an antimicrobial agent is hypothesized to be through the 
inhibition of DNA replication and cellular respiration.145 Other evidence indicates that CO 
causes global changes in gene expression of microorganisms as well as in cell function.145 In 
cancer treatment CO can prevent the expression of proteins that promote cancer, inhibit 
proliferation and induce ROS production.146 The gaseous molecule provides protection 
against malaria by inhibiting the degradation of haemoglobin into free heme.142 This 
subsequently prevents the polymerization of heme into hemozoin. 
 
CO has played a vital role as a therapeutic agent and as a form of treatment for several 
diseases but the administration of CO as gas is not suggested. This is due to its toxicity and 
inability to control the localization or selectivity of gaseous CO.9 CORMs present a safer 
alternative method of CO-administration. CORMs allow for CO-release to be site-specific, 
dose-controlled and intensified presenting a viable approach for antiparasitic treatments that 
use new modes of action.145   
 
1.7.2.2. Non-metallic CORMs 
 
Several purely organic CORMs have been synthesized and reported in the literature. This 
includes methylene chloride which releases CO post degradation. CO-release from methylene 
chloride was used to effectively inhibit allogeneic chronic rejection in rats.147  Motterlini et al. 
identified a boranocarbonate (Na2[H3BCO2]) titled CORM-A1 (Figure 1.27) as an organic 












Ayudhya et al. synthesized the first example of an amine carboxyboranes that releases CO 
under physiological conditions.148 Wang et al. report on molecules that release CO via a “click-
and-release” (CNR) mechanism.149 In this method, the compounds are stable on their own but 
can react with each other to release CO. An example is tetraphenylcyclopentadienone (6a in 
Figure 1.28, TPCPD) and bicyclo-[6.1.0]nonyne (7a, BCN) which react via an inverse electron 
demand Dield-Alder reaction to release CO. Although these examples release CO via 






Figure 1.28. Inverse electron demand Dield-Alder reaction between 
tetraphenylcyclopentadienone (TPCPD, 6a) and bicyclo-[6.1.0]nonyne (BCN, 7a) to release CO 
Figure 1.27. CORM-A1 identified by Motterlini et al. as an organic CO-releasing molecule in 
aqueous solution.128 
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Examples of unsaturated cyclic α-diketones,150 xanthene carboxylic acids,151 meso-carboxy 
BODIPY,152 and hydroxyflavone derivatives,153 have all shown photoCORM properties. Due to 
the relatively recent development of organic CORMs, their biological applications are not 
established. Organic CORMs are also less advantageous than those containing metal centres 
due to the lower CO content and production of organic byproducts.154   
 
1.7.2.3. Group 7 transition metal PhotoCORMs 
 
The medicinal uses of light and its role in the activation of processes in metal complexes have 
been explored for over a decade.155 The study of the photo-physics and photo-chemistry of 
CORMs led to the discovery of photoCORMs.125 PhotoCORMs (photo-activated CO-releasing 
molecules) are CO donors that release CO upon illumination of light of the correct 
wavelength.156   
 
In order for CO to be delivered to the biological target upon illumination, the metal carbonyl 
complex needs to be stable in aqueous solutions in the dark for long periods of time.157 Upon 
illumination, one (or more) CO molecules will be released, while the remaining metal complex 
remains intact, as seen in Figure 1.29.157 The released CO is transported to the biological 
target while the remaining metal complex is likely to bind to a solvent molecule in order to 










Several metals are used in the synthesis of CORMs but the use of Mn(I) in photoCORMs is 
popular due to the thermal stability associated with the metal in this oxidation state, as well 
Figure 1.29. General method of photo-activated CO-release.159 
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as the easy synthesis and low toxicity of these compounds.9 Mn(I) and Re(I) metal carbonyls 
have a low spin d6 configuration and are studied due to their extensive photo-physical and 
photochemical properties.158  These transition metal complexes exhibit a clear MLCT 
transition that favourably labilizes the metal-CO bond promoting CO-release. Mn carbonyls 
release CO quickly upon exposure to visible light, as opposed to its Re analogues which are 
only photoactivated upon exposure to UV light.159 Several manganese photoCORMs have 
been reported, where CO-release was monitored intracellularly, using blue 
fluorescence.125,156 Many manganese photoCORMs have mainly been studied for their 
physical properties and ability to release CO upon irradiation.9,160 These complexes may 
potentially be studied further for the targeted release of CO into cellular systems.160  
 
Dimanganese decacarbonyl [Mn2(CO)10) is one of  the first Mn PhotoCORMs identified by 
Moterlinni et al.139, although the complex was not referred to as a photoCORM at the time. 
[Mn2(CO)10] releases CO upon photodissociation and can cause heart vasoconstriction in rats. 
 
Poole et al. synthesized a water-soluble Mn PhotoCORM, [Mn(CO)3(tpa-κ3N]Br (Figure 
1.30).161 The complex was found to be stable in solution and released CO upon illumination 
of light at 365 nm. The complex was also found to be toxic to the Escherichia coli strain K-12 














Figure 1.30. Structure of metal carbonyl complex, [Mn(CO)3(tpa-κ3N]Br synthesized by 
Poole et al.163 
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Tutar et al. synthesized several manganese photoCORMs, two of which are shown in Figure 
1.31. These complexes were evaluated for their CO-releasing and anticancer properties 













In the absence of irradiation, the complexes exhibited low toxicity towards the cancer cells, 
but upon irradiation at 365 nm, the complexes inhibited cell proliferation.116  
 
Kianfar et al. reports on three rhenium tricarbonyl compounds, shown in Figure 1.32 that 
exhibits selective photochemical CO-release. These compounds all have low quantum yields, 
making them suitable for the potential study as photoCORMs without quickly reaching 











Figure 1.31. PhotoCORMs synthesized by Tutar et al. that show anticancer properties.117  
Figure 1.32. Rhenium PhotoCORMs that exhibits photochemical CO-release and non-
cytotoxic CO concentrations.  
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1.7.2.4. CORMs used to treat malaria 
 
No recorded reports were found in which group 7 transition metal CORMs are evaluated for 
the treatment of malaria. In general, the study of CORMs/photoCORMs revolves mostly 
around the treatment of cancer and its potential use as an antimalarial agent has only been 
explored in one study. Pena et al. synthesized a ruthenium-based metal carbonyl in Figure 













The Ru(II) complex  (ALF492) protected mice from ECM (experimental cerebral malaria) and 
also induced the production of heme oxygenase 1 (HO-1) which has previously been proven 
to protect mice against ECM.142 The study indicated that when the CORM was used in 
combination with the antimalarial drug artesunate, the efficacy of the combined compounds 
was increased and the immune response of the mice was enhanced.115 This study becomes 
pivotal in drug design and certainly supports the investigation of CORMs as a new mode of 
action for antimalarial treatment. 
 
1.8. Rationale and motivation for the current study 
 
The prevalence and consistent emergence of resistant strains of malaria to all known 
antimalarial drugs is a clear indication that there is a need for new innovative treatments. It 
is essential that these compounds explore a new mode of action. The shocking statistics that 
the disease mainly claims the lives of pregnant women and children under the age of 5 
Figure 1.33. Ru (II) complex ((ALF492) that effectively protects mice against experimental 
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motivates the investigation of new treatments. This study is also motivated by the fact that 
the majority of cases and fatalities occur on the African continent. Literature reports several 
beneficial biological activities of CORMs as well as the therapeutic use and extensive research 
into its anti-cancer properties. There is only a single study that evaluates a CORM for its 
antimalarial properties, despite the potential CO has as an antimalarial agent.  
Chloroquine-triazole hybrids have proven to exhibit high potency against several strains of P. 
falciparum. For this reason, it is worth investigating the effects of incorporating these hybrid 
molecules into a CO-releasing framework. It is possible that in addition to the antimalarial 
properties of the two known antimalarial pharmacophores, CO-release may increase the 
potency of the parent molecules. While conducting this literature review, no metal carbonyl 
chloroquine-triazole hybrid molecules were found, but the several reports on chloroquine-
derivative complexes make for a good argument in favor of a further investigation of such 
compounds. The addition of a triazole moiety is done on the basis that triazole compounds 
have also shown antiplasmodial activity against P. falciparum. 
 
1.9. Aims and Objectives 
1.9.1. General aims 
 
As discussed in this chapter, there is a lack of research focussed on the antimalarial evaluation 
of carbon monoxide and CORMs/PhotoCORMs. The aims of this project were: 
• To synthesize and characterize two quinoline-1,2,3-triazole ligands. 
• To complex these ligands to an Mn(I) and Re(I) tricarbonyl core. 
• To perform reactivity studies on the Mn(I) complexes. 
• To evaluate the in vitro antiplasmodial activity of the parent ligand and their 
respective complexes. 
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1.9.2. Specific objectives 
 
The specific objectives were to: 
• Synthesize an aryl ether via a Schiff base condensation reaction followed by a 






• Synthesize 4-azido-7-chloroquinoline via a nucleophilic aromatic substitution 






• Synthesize N-(3-azidopropyl)-7-chloroquinolin-4-amine (Scheme 1.3) 
Scheme 1.1. Reaction scheme for the synthesis of the aryl ether (2). Reagents and conditions: 
(i) MeOH, reflux, 21 h; (ii) Acetone, K2CO3, 18-crown-6, reflux, 72 h.  
Scheme 1.2. Synthetic route for the synthesis of 4-azido-7-chloroquinoline (3). Conditions: (iii) 
DMF, reflux, 6 h.  
  


















• Synthesize a 7-chloroquinoline-1,2,3-triazole and a 4-amino-7-chloproquinoline-













Scheme 1.3. Synthetic scheme for 4-amino-7-chloroquinoline intermediates 4, 5a,5b and 6. 
Conditions: (iv) neat, 180 ℃, 1 h; (v) 130℃, 16 h; (vi) cat.DMF, reflux, 16 h; (vii) THF, NEt3, 
0℃, 3 h; (viii) DMF, relux, 18 h; (ix) DMF 4 h. 
Scheme 1.4. Synthetic scheme for the CuAAC of L1 and L2. Conditions: (x) DCM,CuI, DIPEA,           
reflux, 4 h, (xi) DCM,CuI, DIPEA, reflux, 18 h. 
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• Perform reactivity studies on complex Mn-1 using an [2+1] approach to synthesize a 










Scheme 1.5. Synthetic scheme for the complexation of ligands L1 and L2. Conditions: (xii) 
Mn-1: DCM, rt, 72 h. Re-1: DCM, reflux, 96 h. (xiii) Mn-2: DCM, 25, 24 h. Re-2: DCM, 40, 
24 h.  
 
 
Scheme 1.6. Synthetic route taken for the synthesis of cationic Mn-1. Conditions: (xiv) 
MeCN, rt, 22.5 h. 
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• Characterize the compounds using various spectroscopic and analytical techniques 
such as Nuclear Magnetic Resonance spectroscopy (NMR), Fourier Transform- 
Infrared spectroscopy (FT-IR), Elemental Analysis (EA) and Electrospray Ionisation 
(ESI) mass spectrometry.  
• Evaluate antimalarial and light-induced CO-releasing properties of metal tricarbonyl 
complexes to determine if the production of CO confers the compounds more toxic 
to the parasite.  
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Chapter 2 
Synthesis and characterization of quinoline-1,2,3-
triazole ligands  
 
2.1.  Introduction 
 
Chloroquine (CQ) (Figure 2.1) is one of the most significantly studied quinoline-containing 
antimalarial drugs due to its low toxicity, easy synthesis, good pharmacokinetic properties 
and few side effects.1 However, its success and overuse have led to the development of CQ-
resistant strains of P.falciparum and P.vivax, the two strains responsible for most malaria 
deaths.2 Various structurally dissimilar alternative antimalarials have since been synthesized, 
including primaquine,3 mefloquine4 and artemisinins,5 some of which are still used today. 
However, none of these drugs have shown the same pharmacological profile exhibited by 
CQ.6 Due to the unmatched efficacy of chloroquine, scientists have focussed on the 






Figure 2.1. Chemical structure of chloroquine.6 
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Many chloroquine derivatives have been reported, including compounds where the side chain 
of CQ is modified with α,β-unsaturated amides and benzyl groups.7 Kaschula et al. focussed 
on the derivatization of ring A on the quinoline scaffold of CQ, where the chloro group at 
position-7 was substituted with electron-withdrawing and electro-donating groups: NH2, OH, 
OCH3, H, CH3.8 Pou et al.  modified the B ring with alkyl or aryl substituents in the 3-positon 
and altered the side chain in the 4-position. These compounds have relatively low 𝐼𝐶50 values 
in the range 8-20 nm.9  
Quinoline-containing antimalarials have been used as mainstays of chemotherapy against 
malaria.10 A modern approach in drug design has been molecular hybridization, which 
involves covalent bonding between two or more known pharmacophores.10 Many quinoline-
based hybrid compounds have been synthesized and evaluated for their antimalarial activity, 
showing promising antiparasitic activity.11 Wang et al. synthesized artesunate-quinoline 
hybrids, which showed greater antimalarial activity than the individual drugs.12 N’Da et al. 
reported a series of quinoline-ferrocene hybrids that show greater antimalarial activity than 
equimolar amounts of the individual drugs in the Dd2-CQ-resistant strain of P.falciparum.13 
Other quinoline hybrid antimalarial compounds include quinoline-pyrimidines,14  quinoline-
trioxolanes,15 and quinoline-triazole hybrids which have shown appreciable antimalarial 
activity in several studies.16,17,18  
Triazoles, in particular, have shown to possess many pharmacological properties and have 
become widely used in medicinal chemistry due to their resistance to metabolic degradation 
and the capability of forming hydrogen bonds.19 Triazoles can take part in various non-
covalent interactions, improving their solubility and ability to bind to biomolecular targets.20  
Boechat et al. synthesized a series of quinoline-1,2,3-triazole compounds with varying R 
substituents in the 4‐position of 1H‐1,2,3‐triazol‐1‐yl.21 The compound bearing an aldehyde 
in the 4-position (Figure 2.2.) was the most active against the W2-CQ-resistant strain of 
P.falciparum with an 𝐼𝐶50 value of 1.4 μM. 
 
  










Faidallah et al. synthesized a series of 1,2,3-triazole-quinine conjugates with varying R-
substituents in the 1-position of the triazole ring.22 The conjugate shown in Figure 2.3, shows 









Molecular hybridization is an exciting prospect and the good antimalarial activity exhibited by 
many quinoline-triazole hybrids reported in the literature motivates the current study.  In this 
chapter, the synthesis and characterization of two new quinoline-triazole ligands (a molecule 
that binds to a central metal atom to form a complex) are discussed. These two triazole 
ligands vary in the 4-position, one having the triazole ring attached directly in the 4-position 
Figure 2.2. 1H‐1,2,3‐Triazole‐Quinoline hybrid synthesised by Boechat et al. shown to 
have good antimalarial activity against W2-CQ-resistant strain of P. falciparum.21 
Figure 2.3. Quinoline-triazole conjugates synthesized by Faidallah et al. shown to have good 
antimalarial activity.22  
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whereas the second has the quinoline ring and triazole moiety separated by an amino-propyl 
chain. Several series of 7-chloroquinoline-triazole hybrids with varying substituents on the 
triazole moiety have been evaluated for their antiplasmodial activity in literature.23,21 Some 
showing appreciable activity in CQ-resistant strains of P.falciparum. It has been established 
that the presence of an amino side chain on the quinoline ring plays an important role in the 
antimalarial activity of the hybrids.16,24 It is for this reason that two 7-chloroquinoline-triazoles 
were synthesized.  The difference in antimalarial activity exhibited by the compounds with 
the triazole moiety attached directly in the 4-position compared to those containing a basic 
amino-propyl chain in the 4-position of the quinoline ring is discussed in Chapter 4.  
 
2.2. Synthesis of quinoline-1,2,3-triazole ligands using “click 
chemistry” 
 
The 7-chloroquinoline-triazole ligands were synthesized via a copper-catalysed azide/alkyne 
1,4-dipolar cycloaddition which makes use of two components: an alkyne and azide. These 
reactions have been called ‘click chemistry’, as coined by Sharpless in 2001.25 Click chemistry 
has become a highly favourable synthetic route due to its reliability and selectivity.26 
Sharpless et al. defines click chemistry by the following criteria: high yielding, produces easily 
removable by-products,  uses mild reaction conditions and makes use of benign solvents that 
are easily removed.25 Among all the “click reactions”, the Huisgen 1,3-dipolar cycloaddition 
between alkynes and azides is the leading example,26 but it requires high temperatures and 
produces both regioisomers (1,4- and 1,5-disubstituted) when asymmetric alkynes are used. 
The copper-catalysed azide/alkyne 1,4-dipolar cycloaddition (CuAAC) reaction was developed 
as a method with a wider reaction scope.27 The CuAA reaction succeeds under a wide range 
of temperatures and is insensitive to pH changes between 4 and 12. An organic azide and 
terminal alkyne is reacted together to regioselectively form a 1,4-disubstituted 1,2,3-
triazole.28 Herein is reported the copper-catalysed cycloadditions of a terminal alkyne to two 
different azido-chloroquinolines to produce two new quinoline-1,2,3-triazole ligands.   
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2.2.1.  Synthesis of terminal alkyne.29 
 
The alkyne component (2) of the triazole was synthesized from a precursor, 4-
(pyridinylimine)phenol (1). Compounds 1 and 2 were synthesized following published 






For the synthesis of compound 1, a Schiff base condensation was carried out by reacting 4-
aminophenol with 2-pyridinecarboxaldehyde. A Schiff base condensation reaction occurs 
between an aldehyde/ketone and primary amine to form an imine or “Schiff base “as shown 
in Scheme 2.2.30 Compound 1 was isolated as a yellow crystalline solid in high yield of 84% 
with a melting point range of 186.2-187.8 ℃ that correlates with that reported in the 








Propargylation of compound 1, involved the reaction with K2CO3 as the base and 18-crown-6 
as the phase-transfer catalyst via a Williamson-ether reaction. Propargyl bromide was 
subsequently added and the reaction proceeded via an SN2 reaction mechanism. Compound 
Scheme 2.1. Reaction scheme for the synthesis of the aryl ether (2). Conditions: (i) MeOH, 
reflux, 21 h; (ii) Acetone, K2CO3, 18-crown-6, reflux, 72 h.  
Scheme 2.2. General mechanism for the Schiff base condensation reaction between aldehydes 
and primary amines.31  
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2 was isolated as brown crystals in a high yield of 81%. It has a melting point range of 104.4-
106.2 ℃. The Williamson-ether reaction follows an SN2 mechanism in which an alkyl halide 
reacts with an alcohol under basic conditions to form an ether.31 Under these conditions, the 
alcohol is deprotonated to form a phenoxide, which reacts faster with the alkyl halide. This is 
due to an increased electron density on the nucleophile which attacks the electrophilic carbon 









18-Crown-6 is added due to the poor solubility of the phenoxide intermediate in organic 
media. The phase transfer catalyst facilitates the migration of the solid into the solvent so the 
reaction may proceed. 18-Crown-6 encapsulates K+ subsequently improving the solubility and 




The Schiff base (1) and aryl ether (2) were characterized using 1H NMR, 13C{1H} NMR and 
infrared (IR) spectroscopy. The carbon signals were assigned using HSQC. 
 
2.2.2.1. 1H and 13C{1H} NMR spectroscopy  
 
The 1H NMR spectrum of compound 1 (Figure 2.4) shows a distinctive singlet at 9.61 ppm for 
the phenolic proton and another singlet at 8.67 ppm corresponding to the imine proton (H-
Scheme 2.3. General mechanism of a Williamson ether reaction.33 
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6). The α-Npyr proton appears as a doublet at 8.67 ppm with a coupling constant of                    
3JHH= 4.8 Hz. Protons H-9 and H-8 are observed as doublets at 7.28 ppm and 6.82 ppm 
respectively, with coupling constants of 3JHH= 8.70 ppm. Each signal integrates for the 
expected two protons due to the equivalent chemical environment of each set of protons. In 
the 13C{1H} NMR spectrum of compound 1, the most deshielded signal at 156.99 ppm 
corresponds to C-10. The imine carbon C-6 appears as a singlet at 156.88 ppm, while the 
quaternary carbons C-5 and C-7 are seen at 141.49 ppm and 154.52 ppm respectively.  
In the 1H NMR spectrum of compound 2 (Figure 2.4) the phenolic proton signal seen in the 
spectrum of compound 1 is no longer present. H-11 is assigned to the doublet integrating for 
two protons and H-13 to the triplet integrating for one proton in the aliphatic region at         
4.83 ppm and 3.56 ppm respectively. Each signal has a coupling constant of 4JHH= 2.4 Hz. The 
presence of protons H-11 and H-13 in the respective aliphatic region is indicative of successful 
propargylation. The imine proton (H-6) is assigned as the singlet at 8.69 ppm, showing a shift 
from 8.58 ppm for compound 1. The C-10 singlet has shifted upfield from 156.99 ppm 
(compound 1) to 156.39 ppm (compound 2) in the 13C{1H} spectrum of compound 2. This shift 
is a result of the increased electron density in the alkyne substituent.  Three signals appear in 






















Figure 2.4. Stacked 1H NMR spectra of compounds 1 (bottom) and 2 (top). 
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2.2.2.2. IR spectroscopy 
 
The IR spectrum of compound 1 shows characteristic absorption bands at 1623 𝑐𝑚−1 and 
1581 𝑐𝑚−1, corresponding to the imine C=N and pyridyl C=N functional groups respectively, 
further confirming the formation of the Schiff base. A broad absorption band is seen between 
2465-2988 𝑐𝑚−1 and is assigned to the aromatic C-H’s and the hydroxyl (OH) functionality. In 
the IR spectrum of compound 2, diagnostic absorption bands at 3171 𝑐𝑚−1 and 2964 𝑐𝑚−1 
are seen for the H-C≡ and C≡C functional groups respectively. The imine and pyridyl C=N 
absorption bands appear at 1623 𝑐𝑚−1 and 1600 𝑐𝑚−1 respectively. The asymmetric stretch 
of the ether (C-O-C) appears as a strong absorption band at 1239 𝑐𝑚−1. 
 
2.2.3. Synthesis of 4-azido-7-chloroquinoline (3).34 
 
The first azide components for the CuAAC reaction was synthesized using a method adapted 
from literature.34 The azido-quinoline, compound 3 was synthesized via a Nucleophilic 
Aromatic substitution (SNAr) reaction between 4,7-dichloroquinoline and sodium azide, as 
shown in Scheme 2.4. Compound 3 was isolated as yellow needle-like crystals in a moderate 
yield (62%) with a melting point range of 116.3-118.5 ℃. This experimental range corresponds 








 An SNAr reaction is an organic substitution reaction in which a nucleophile replaces a leaving 
group on an aromatic ring. The substitution of aromatic rings containing a heteroatom is more 
likely to occur when an electron-withdrawing group is ortho or para to the leaving group.  
Scheme 2.4. Synthesis of 4-azido-7-chloroquinoline (3). Conditions: (i) DMF, reflux, 6 h.  
  








Substitution, therefore, occurs exclusively at the 4-position as opposed to the 7-position of 
4,7-dichloroquinoline. The para-electron-withdrawing nitrogen stabilizes the Meisenheimer 
intermediate through resonance as shown in Scheme 2.5. This stabilization results in 
substitution occurring in the 4- as opposed to the 7-position. 
 
2.2.4. Characterization 
2.2.4.1. 1H and 13C{1H} NMR spectroscopy 
 
The proton resonance of H-2 shifts upfield from 7.49 ppm in 4,7-dichloroquinoline to 7.13 
ppm for compound 3, as seen in the 1H NMR spectra in Figure 2.5. This upfield shift is 
indicative of the weaker electron-withdrawing effect of the azido entity compared to the 
stronger electron-withdrawing inductive effect caused by the chloride. Protons H-5, H-6, H-8 
all undergo upfield shifts upon azidation due to the same phenomenon. H-5 appears as a 
doublet of doublets at 7.49 ppm with coupling constants 3JHH= 8.94 Hz and 5JHH= 2.07 Hz, 
indicating that it couples to H-6 as well as H-8. H-1 undergoes a downfield shift from 8.78 ppm 
to 8.83 ppm. The 13C{1H} NMR spectrum of compound 3 shows the C-1 singlet as the most 
deshielded carbon at 151.37 ppm.  
 
Scheme 2.5. Mechanism for the azidation of 4,7-dichloroquinoline via SNAr. 
  














2.2.4.2. IR spectroscopy 
 
The IR spectrum of compound 3 shows an azide (N3) absorption band in the characteristic 
region at 2117 𝑐𝑚−1, a quinoline C=N band at 1608 𝑐𝑚−1 and a C-Cl absorption band at   766 
𝑐𝑚−1.  
 
2.2.5. Synthesis of N-(3-azidopropyl)-7-chloroquinolin-4-amine.35  
 
A second azido-quinoline was synthesized, in which the azide entity is on the terminal end of 
an amino-propyl chain on the quinoline ring (6). A series of intermediates (compounds 4, 5a 
and 5b) were first synthesized.  
4,7-Dichloroquinoline was reacted with 3-aminopropan-1-ol following a known method, 35 to 
form the amino alcohol compound 4 as shown in Scheme 2.6 (conditions i and ii). This 
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Figure 2.5. Stacked 1H NMR spectra of 4,7-dichloroquinoline (bottom) and compound 3 (top). 
  


















Two routes were explored for the synthesis of the azido precursor in order to optimize the 
reaction. The first route involved the synthesis of a chloro intermediate (5a) whereas the 
second route involved the synthesis of a methanesulfonyl intermediate (5b). The reaction of 
the chloro intermediate (5a) with NaN3 produced a low yield of the final azide (6), hence the 
second intermediate (5b) was synthesized. Compound 4 was reacted with either thionyl 
chloride (SOCl2) or methanesulfonyl chloride (MsCl) via Nucleophilic substitution (SN2) 
reactions described in the literature.35,36 These reactions afforded beige solids in moderate 
yields of 67% for 5a and 53% for 5b. Compounds 5a and 5b were reacted with NaN3 under 
similar conditions shown in Scheme 2.6 (conditions v and vi). These reactions afforded 
compound 6 as pale-yellow solids in a low yield of 23% using 5a as a precursor and a moderate 
yield of 56% using 5b as the precursor. 
Scheme 2.6. Synthetic scheme for 4-amino-7-chloroquinoline intermediates 4, 5a,5b and 
the final product compound 6. Conditions: (i) 180 ℃, 1 h; (ii) 130 ℃, 16 h; (iii) cat. DMF, 
reflux, 16 h; (iv) THF, NEt3, 0 ℃, 3 h; (v) NaN3, DMF, 80 ℃, 18 h; (vi) NaN3, DMF, 55 ℃ 4 h. 
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2.2.6. Characterization 
 
The 4-amino-7-chloroquinoline intermediates (4, 5a and 5b) and azide (6) were characterized 
using 1H NMR, 13C{1H} NMR and infrared (IR) spectroscopy. 
 
2.2.6.1. 1H and 13C{1H} NMR spectroscopy 
 
In the 1H NMR spectrum of compound 4 (Figure 2.6), the most deshielded signal at 8.39 ppm 
is assigned to H-7. The amine proton H-4 is observed as a broad signal at 7.27 ppm and the 
hydroxyl proton as a broad signal at 4.56 ppm. The propyl chain protons are identified as the 
triplet at 3.55 ppm, a signal at 3.33 ppm, not well resolved from the H2O resonance and the 
quintet at 1.82 ppm. These signals correspond to protons H-1, H-3 and H-2 respectively.  The 
H-1 and H-2 signals integrate for the expected two protons. The presence of the H-3 signal 
was confirmed using HSQC, indicated by a cross peak at 3.33 ppm; 117.74 ppm. The cross 
peak is assigned to that of H-3; C-3. Protons H-6, H-9 and H-11 are seen as doublets at 6.47 
ppm, 7.77 ppm, and 8.24 ppm. The doublet of doublets at 7.43 ppm with coupling constants 
3JHH= 9.00 Hz and 5JHH= 1.6 Hz is assigned to H-12. The coupling constants suggest that H-12 
couples to H-11 and H-9. C-5 is observed as the most deshielded signal at 151.91 ppm in the 
13C{1H} NMR spectrum of compound 4. All remaining aromatic carbon signals are accounted 
for and appear as singlets between 150.4 ppm and 98.56 ppm. Aliphatic carbons C-1, C-3, and 
C-2 are assigned to the signals at 48.46 ppm, 40.94 ppm, and 31.23 ppm respectively. 
 Analysis and comparison of the 1H NMR spectra of compounds 4, 5a and 5b (Figure 2.6) show 
the successful transformation of the hydroxyl (OH) functionality to a chloride and 
methanesulfonyl. The hydroxyl proton signal seen in the 1H NMR spectrum of compound 4, is 
no longer present in the spectra of compounds 5a and 5b. The amine proton (H-4) shifts 
downfield from 7.27 ppm to 9.50 ppm upon the formation of the alkyl halide, due to the 
greater inductive electron-withdrawing effect of the chloride compared to that of the 
hydroxyl group. There are significant downfield shifts of the aromatic proton resonances of 
compound 5a, as seen in Figure 2.6. These shifts may be due to the possible reaction of the 
quinoline nitrogen with the sulfur of SOCl2. This would explain the low yield of compound 6 
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produced from reaction condition v in Scheme 2.6. Further analysis such as mass 



















Upon the formation of the methanesulfonyl intermediate (5b), the amine proton (H-4) signal 
is observed at a similar frequency (7.31 ppm) to the precursor alcohol (7.27 ppm). The intense 
singlet at 3.19 ppm, integrating for three methyl protons in the spectrum of 5b, is the 
diagnostic signal for the successful mesylation.  In the 13C{1H} NMR spectrum of compound 
5a, C-5 resonates downfield at 155.11 ppm. C-1, C-3 and C-2 signals have shifted upfield to 
44.20 ppm, 39.88 and 30.96 ppm, owing to the electron-withdrawing nature of the Cl. All 
carbon signals in the 13C{1H} NMR spectrum of 5b are accounted for and only undergo slight 
shifts due to their similar electronic environments in the alcohol precursor and 
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Azidation of compound 5a was more apparent in the 1H NMR spectroscopy than that of 5b. 
Comparison of the 1H NMR spectra of 5a and 6 shows an upfield shift of the imine proton (H-
4) from 9.50 ppm to 7.30 ppm. All aromatic and aliphatic protons shift upfield with chemical 
shifts resembling those observed for the aminopropanol precursor, compound 4. The 
aliphatic protons H-1, H-3, and H-2 are observed as a triplet at 3.50 ppm, a doublet of doublets 
at 3.63 ppm and a quintet at 1.93 ppm. This upfield shift of the aliphatic protons is attributed 
to the weaker electron-withdrawing nature of the azide moiety in comparison to the 
chloride.1H NMR spectral analysis of 5b and 6, indicates that the aliphatic protons all undergo 
upfield shifts upon azidation. The proton resonance of H-1 shifts from 4.34 ppm to 3.50 ppm, 
H-3 from 3.39 ppm to 3.38-3.33 ppm and H-2 from 2.08 ppm to 1.93 ppm. The 13C{1H} NMR 
spectrum of compound 6, shows the aliphatic carbon signal C-1, C-3, and C-2 at 48.53 ppm, 
40.10 ppm, and 27.09 ppm respectively.   
 
2.2.6.2. IR spectroscopy 
 
 A broad absorption band at 3312 cm-1 is seen in the IR spectrum of compound 4, corresponding 
to the hydroxy (OH) functionality. A weak sharp absorption band is seen at 3058 cm-1 
corresponding to the secondary amine and a strong sharp band at 1609 cm-1 for the quinoline 
C=N. The electronic properties of the chloride are seen in the IR spectrum of compound 5a, as 
the amine absorption band shifts to a higher wavenumber of 3219 𝑐𝑚−1 and that of the quinoline 
shifts to a higher wavenumber of 1614 𝑐𝑚−1.The distinctive OH band is no longer present in the 
IR spectrum of compound 5a while there is an absorption band at 734 𝑐𝑚−1 for the C-Cl stretch. 
The IR spectrum of compound 5b shows the secondary amine absorption band at 3065 𝑐𝑚−1 
and the absorption band observed at 1609 𝑐𝑚−1 is assigned to the quinoline C=N stretch. The 
IR spectrum of 6 has a strong sharp absorption band at 2111 𝑐𝑚−1 corresponding to the azide 
moiety and a sharp strong band at 3191 𝑐𝑚−1 for the secondary amine. The quinoline C=N 
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2.2.7. Synthesis of the 7-chloroquinoline-1,2,3-triazole ligand (L1) using “click 
chemistry”. 
 
Click chemistry has also been said to be “green” as it often proceeds in aqueous media, 
making this type of chemistry appealing.37, 38 However, in order to synthesize the desired 
ligands, DCM was required as a solvent.  
The quinoline-1,2,3-triazole ligand L1 was synthesized using the CuAAC reaction.39 4-Azido-7-
chloroquinoline (3) was reacted with (E)-N-(4(prop-2-yn-1-yloxy)phenyl)-1-(pyridine-2-
yl)methanimine (2)  as outlined in Scheme 2.7. L1 was isolated as a beige solid in a moderate 
yield of 56% and is soluble in chlorinated solvents like DCM and chloroform, partially soluble 












CuAAC or ‘click’ reactions are copper-catalysed reactions between terminal alkynes and 
azides to regioselectively form a 1,4-disubstituted 1,2,3-triazole.40 Cu(I) is the active catalyst 
that leads to the exclusive synthesis of the 1,4-disubstituted regioisomer.41 CuI exists in an 
inactive polymeric form and therefore is dissociated by an amine to form the active Cu(I) 
species.39 N, N-diisopropylethylamine (DIPEA) is used as a base to pre-activate CuI by forming 
Scheme 2.7. Reaction scheme for the synthesis of L1 using a copper-catalysed azide/alkyne 
cycloaddition. Conditions: (i) DCM, CuI, N,N-diisopropylethylamine (DIPEA), reflux, 4 h.  
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a copper(I)-acetylide complex as shown in Scheme 2.8.40,42 The formation of a Cu(I) acetylide 













The σ-bound Cu(I) acetylide has a π-bound copper which coordinates to the azide forming a 
six-membered copper metallacycle. The second Cu atom acts as a stabilizing donor ligand. 
Ring contraction occurs forming a triazolyl-copper intermediate which then undergoes 
protonolysis yielding the desired triazole. 
 
2.2.8. Characterization 
2.2.8.1. 1H and 13C{1H} NMR spectroscopy 
 
The diagnostic triazole proton signal H-13 is seen in the 1H NMR spectrum of L1 as a singlet at 
9.00 ppm. The methylene protons H-11 appear as a singlet at 5.37 ppm but as a doublet with 
a coupling constant of 3JHH= 2.4 Hz in the 1H NMR spectrum of compound 2. Upon 
cycloaddition, protons H-11 no longer couple to H-13 as was observed for compound 2. All 
Scheme 2.8. General mechanism of CuAAC reactions.40 
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quinoline aromatic protons except H-18 shifts downfield upon cycloaddition, as the triazole 
ring is more electron-withdrawing than the azide. The H-15(*) doublet has shifted to a higher 
frequency at 7.95 ppm compared to its initial frequency at 7.13 ppm in 3. The H-20 (*) doublet 
of doublets is observed at a lower frequency (7.86 ppm) compared to its initial chemical shift 
at 8.94 ppm in compound 2. Spectral analysis of the 13C{1H} NMR spectrum of L1 shows the 
triazole carbon C-13 signal at 124.32 ppm. This lies in the characteristic region of 1,4-















2.2.8.2. IR spectroscopy 
 
IR spectroscopy is a useful technique for the elucidation of successful synthesis of the 
quinoline-triazole ligand. The azide absorption band at 2117 𝑐𝑚−1 (compound 3) is no longer 


















Figure 2.7. Stacked 1H NMR spectra of azido-quinoline (3) (top), the precursor alkyne (2) 
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slightly from 1608 𝑐𝑚−1 to 1610 𝑐𝑚−1. The imine and pyridyl C=N bands are found at 1623 












2.2.9.  Synthesis of 4-amino-7-chloroquinoline-1,2,3-triazole   ligand (L2) 
 
L2 was synthesized via a CuAAC reaction between compounds 6 and 2, as outlined in Scheme 
2.9. The reaction follows the same mechanism described in Section 2.2.6. L2 was isolated as 










Scheme 2.9. Synthetic scheme for the CuAAC of L2. Conditions: (i) DCM,CuI, DIPEA,           
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L2 is a new aminoquinoline-1,2,3-triazole that is soluble in most polar organic solvents like 
DCM, DMSO, ethyl acetate, methanol, acetone, ethanol, and chloroform. Contradictory to 
what is expected from click reactions, the synthesis of ligand L2 was slightly more challenging 
than L1. Ligand L2 was isolated via the slow diffusion out of diethyl ether and gave a moderate 
yield of 42%. The reaction time was longer than expected, taking 18 hours for the reaction to 
proceed to completion.  
 
2.2.10. Characterization 
2.2.10.1. 1H and 13C{1H} NMR spectroscopy 
 
The 1H NMR spectrum of L2 (Figure 2.9) shows the diagnostic triazole H-13 proton signal as a 
singlet at 8.28 ppm. The methylene protons H-11 are observed as a singlet at 5.18 ppm and 
has undergone a downfield shift from 4.83 ppm (compound 2). This shift is attributed to the 
more electron-withdrawing nature of the triazole ring. H-11 no longer appears as a doublet, 
as was seen in the spectrum of compound 2 and therefore no longer couples to H-13. The 
amine proton H-17 experiences a negligible migration from 7.30 ppm in 6 to 7.34 ppm. 
Protons H-15 and H-14 undergo a downfield shift from 1.93 ppm and 3.50 ppm to 2.25 ppm 
and 4.54 ppm respectively. As observed for compound 4, proton H-16 is not well resolved 
from the H2O resonance at 3.33 ppm, which was confirmed by HSQC. A cross peak is seen at 
(3.33 ppm; 39.74 ppm) corresponding to that of (H-16; C-16). In the 13C{1H} NMR spectrum of 
L2, C-13 appears in the characteristic region at 125.67 ppm. C-1 appears as a singlet at 149.97 




























2.2.10.2. IR Spectroscopy 
 
The imine C=N and quinoline C=N functional groups are observed as a weak sharp absorption 
band at 1612 𝑐𝑚−1 in the IR spectrum of L2, as seen in Figure 2.10. The pyridyl absorption 








































































A quinoline-1,2,3-triazole and an aminoquinoline-1,2,3-triazole ligand were successfully 
synthesized via CuAAC reactions to yield 1,4-disubstituted ligands L1 and L2. These ligands 
were characterized using 1H NMR, 13C{1H} NMR and FT-IR spectroscopy. Both ligands were 
isolated in moderate yields and were air and moisture stable. The click reactions have been 
described as “green” aqueous reactions in literature.37 This is due to the often mild conditions 
needed and compatibility in H2O.38 It was however found that the CuAAC reactions reported 
herein required DCM as a solvent and slightly longer reaction times for L2. The synthesis and 
purification of these quinoline-triazole ligands were relatively easy as expected from “click 
chemistry”. Easy isolation of the click product is one of the criteria defining “click chemistry”, 
as the reaction produces easily removed by-products and purification should not require 
column chromatography. The yields of these reactions were moderate and could possibly be 
improved in the future by using tris-hydroxypropyltriazolylmethylamine (THPTA). THPTA is a 
water-soluble ligand that is often used in CuAAC reactions to help increase the rate of reaction 
and possibly improve its yield.  The antimalarial properties of the synthesized quinoline-
triazoles were evaluated and are discussed in Chapter 4. 
 
2.4. References  
 
1 P. Bray, B. Park, E. Asadollaly, G. Biagini, J. Jeyadevan, N. Berry, S. Ward and P. O’ 
Neill, Curr. Top. Med. Chem., 2006, 6, 479–507. 
2 T. E. Wellems and C. V Plowe, J. Infect. Dis., 2019, 184, 770–776. 
3 K. K. Singh and S. K. Vingkar, Int. J. Pharm., 2008, 347, 136–143. 
4 C. C. C. Hans O. Lobel, Mark Miani, Tom Eng, Kenneth W. Bernard, Allen 
W.Hightower, Lancet, 1992, 341, 848–851. 
5 D. L. Klayman, Am. Assoc. Adv. Sci., 2016, 228, 1049–1055. 
  
67 Chapter 2     Synthesis and characterization of quinoline-1,2,3-triazole ligands 
6 M. Mushtaque and S. Shahjahan, Eur. J. Med. Chem., 2015, 90, 280–295. 
7 S. J. Yeo, D. X. Liu, H. S. Kim and H. Park, Malar. J., 2017, 16, 1–9. 
8 C. H. Kaschula, T. J. Egan, R. Hunter, N. Basilico, S. Parapini, D. Taramelli, E. Pasini and 
D. Monti, J. Med. Chem., 2002, 45, 3531–3539. 
9 S. Pou, R. W. Winter, A. Nilsen, J. X. Kelly, Y. Li, J. S. Doggett, E. W. Riscoe, K. W. 
Wegmann, D. J. Hinrichs and M. K. Riscoe, Antimicrob. Agents Chemother., 2012, 56, 
3475–3480. 
10 Y. Hu, C. Gao, S. Zhang, L. Xu, Z. Xu and L. Feng, Eur. J. Med. Chem., 2017, 139, 22–47. 
11 X. Nqoro, N. Tobeka and B. A. Aderibigbe, Molecules, 2017, 22, 2268. 
12 N. Wang, K. J. Wicht, E. Shaban, T. A. Ngoc, M. Q. Wang, I. Hayashi, M. I. Hossain, Y. 
Takemasa, M. Kaiser, I. El Tantawy El Sayed, T. J. Egan and T. Inokuchi, 
Medchemcomm, 2014, 5, 927–931. 
13 D. D. N’Da and P. J. Smith, Med. Chem. Res., 2014, 23, 1214–1224. 
14 M. Tripathi, S. I. Khan, P. Ponnan, R. Kholiya and D. S. Rawat, ChemistrySelect, 2017, 2, 
9074–9083. 
15 F. B. El Garah, C. Claparols, F. Benoit-Vical, B. Meunier and A. Robert, Antimicrob. 
Agents Chemother., 2008, 52, 2966–2969. 
16 S. Manohar, S. I. Khan and D. S. Rawat, Chem. Biol. Drug Des., 2011, 78, 124–136. 
17 E. M. Guantai, K. Ncokazi, T. J. Egan, J. Gut, P. J. Rosenthal, P. J. Smith and K. Chibale, 
Bioorganic Med. Chem., 2010, 18, 8243–8256. 
18 R. Raj, P. Singh, P. Singh, J. Gut, P. J. Rosenthal and V. Kumar, Eur. J. Med. Chem., 
2013, 62, 590–596. 
19 R. C. N. R. Corrales, N. B. de Souza, L. S. Pinheiro, C. Abramo, E. S. Coimbra and A. D. 
Da Silva, Biomed. Pharmacother., 2011, 65, 198–203. 
20 X. M. Chu, C. Wang, W. L. Wang, L. L. Liang, W. Liu, K. K. Gong and K. L. Sun, Eur. J. 
Med. Chem., 2019, 166, 206–223. 
  
68 Chapter 2     Synthesis and characterization of quinoline-1,2,3-triazole ligands 
21 N. Boechat, M. D. L. G. Ferreira, L. C. S. Pinheiro, A. M. L. Jesus, M. M. M. Leite, C. C. S. 
Júnior, A. C. C. Aguiar, I. M. De Andrade and A. U. Krettli, Chem. Biol. Drug Des., 2014, 
84, 325–332. 
22 H. M. Faidallah, S. S. Panda, J. C. Serrano, A. S. Girgis, K. A. Khan, K. A. Alamry, T. 
Therathanakorn, M. J. Meyers, F. M. Sverdrup, C. S. Eickhoff, S. G. Getchell and A. R. 
Katritzky, Bioorganic Med. Chem., 2016, 24, 3527–3539. 
23 G. R. Pereira, G. C. Brandão, L. M. Arantes, H. A. De Oliveira, R. C. De Paula, M. F. A. 
Do Nascimento, F. M. Dos Santos, R. K. Da Rocha, J. C. D. Lopes and A. B. De Oliveira, 
Eur. J. Med. Chem., 2014, 73, 295–309. 
24 L. Taleli, C. De Kock, P. J. Smith, S. C. Pelly, M. A. L. Blackie and W. A. L. Van Otterlo, 
Bioorg. Med. Chem., 2015, 23, 4163–4171. 
25 M. G. F. and K. B. S. H. C. Kolb, Angew. Chem - Int. Ed., 2001, 40, 2004–2021. 
26 J. E. Moses and A. D. Moorhouse, Chem. Soc. Rev., 2007, 36, 1249–1262. 
27 F. Himo, T. Lovell, R. Hilgraf, V. V. Rostovtsev, L. Noodleman, K. B. Sharpless and V. V. 
Fokin, J. Am. Chem. Soc., 2005, 127, 210–216. 
28 J. E. Hein and V. V. Fokin, Chem. Soc. Rev., 2010, 39, 1302–1315. 
29 Q. Zhang, H. Su, J. Luo and Y. Wei, Catal. Sci. Technol., 2013, 3, 235–243. 
30 D. A. Xavier, 1 and N. Srividhya, J. Appl. Chem., 2014, 7, 06–15. 
31 H. C. Aspinall, N. Greeves, W. M. Lee, E. G. McIver and P. M. Smith, Tetrahedron Lett., 
1997, 38, 4679–4682. 
32 R. N. B. Robert Thornton Morrison, in Organic chemistry, Prentice Hall, 6th edn., 
1992, pp. 241–242. 
33 D. J. Sam and H. E. Simmons, J. Am. Chem. Soc., 1974, 96, 2252–2253. 
34 G. C. Brandão, F. C. Rocha Missias, L. M. Arantes, L. F. Soares, K. K. Roy, R. J. Doerksen, 
A. Braga de Oliveira and G. R. Pereira, Eur. J. Med. Chem., 2018, 145, 191–205. 
35 P. M. Njogu, J. Gut, P. J. Rosenthal and K. Chibale, ACS Med. Chem. Lett., 2013, 4, 
637–41. 
  
69 Chapter 2     Synthesis and characterization of quinoline-1,2,3-triazole ligands 
36 M. P. Kristina Starcevic, Dijana Pesic, Ana Toplak, Goran Landek, Sulejman Alihodzic, 
Esperanza Herreros, Santiago Ferrer, Radan Spaventi, Eur. J. Med. Chem., 2012, 49, 
365–378. 
37 L. Chen and C. J. Li, Adv. Synth. Catal., 2006, 348, 1459–1484. 
38 L. Li and Z. Zhang, Molecules, 2016, 21, 1–22. 
39  Y. H. Changwei Shao, Xinyan Wang, Qun Zhang, Sheng Luo, Jichen Zhao, J. Org. 
Chem., 2011, 76, 6832–6836. 
40 A. A. H. A. Fuaad, F. Azmi, M. Skwarczynski and I. Toth, Molecules, 2013, 18, 13148–
13174. 
41 J. E. Arg, R. Soc. Chem., 2017, 7, 33967–33973. 
42 V. O. Rodionov, V. V. Fokin and M. G. Finn, Angew. Chem - Int. Ed., 2005, 44, 2210–
2215. 
43 V. A. Online, H. Ben, E. Ayouchia, L. Bahsis, L. R. Domingo and S. Stiriba, R. Soc. Chem., 
2018, 8, 7670–7678. 
44 X. Creary, A. Anderson, C. Brophy, F. Crowell and Z. Funk, J. Org. Chem., 2012, 77, 
8756–8761. 
 
   
 
  
70 Chapter 3  Quinoline-triazole Mn(I) and Re(I) tricarbonyl complexes  
Chapter 3 




Carbon monoxide (CO) is well known for its toxic effects on the oxygen metabolism.1 Despite 
CO’s well-known toxicity, it is reportedly produced in miniscule amounts in mammalian cells 
under stress conditions.2 The gaseous small molecule plays an important physiological role as 
a molecular messenger under stress conditions.3 CO has demonstrated several therapeutic 
effects such as anti-inflammatory,4 antiproliferative5 and antiapoptotic.6 In addition to the 
therapeutic effects displayed by the gasotransmitter (a gaseous compound with a 
biochemical function), the medicinal application of CO extends much further. CO has received 
significant acknowledgement in the medical field for its application and progress in organ 
transplants, including the heart,7 lungs,8 kidneys,9 liver10 and the small intestine.11 However, 
the administration of CO in its gaseous form does not allow for control over localisation, 
concentration or selectivity of CO,12 as shown in Figure 3.1. The toxicity of CO and the 
unpredictability of its administration through inhalation prompted the research of Carbon 
Monoxide-Releasing Molecules (CORMs).  
  














The development of CORMs by Motterlini et al.13 has presented an alternative mode of 
transporting CO via a controllable mechanism.14 CORMs release CO upon exposure to external 
stimuli such as solvent,15 enzymes,16 pH,17 and light (PhotoCORMs).18  Although CORMs that 
release CO spontaneously in aqueous media are popular, this method makes it difficult to 
control the starting time of action.19 PhotoCORMs allow for CO-release to be targeted and 
time-specific. PhotoCORMs release CO upon exposure to light at a specific wavelength and 
present a favourable method of spatial and temporal CO-release control. The majority of 
PhotoCORMs reported to date are based on group 7 transition metals, attributing to their 
extensively studied photochemical and photophysical properties.20 CORMs have been 
evaluated for their antimicrobial activity and have displayed potential against many 
microorganisms including Escherichia coli,21 Staphylococcus aureus,21 and Pseudomonas 
aeruginosa.22 CO has also been used as an effective cancer treatment strategy, due to its 
antiproliferative properties.23 CO  has been found to prevent the development of cerebral 
Figure 3.1. Feasibility of using gaseous CO vs. administration using CORMs.13 
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malaria in mice, making the mice tolerant to P.falciparum.24 The development of CORMs has 
thus presented a novel form of treating the before-mentioned diseases and has become of 
great interest in both the scientific and medical field. 
There are several methods that can be used to test the CO-releasing properties of a CORM, 
but the most widely used is a Myoglobin (Mb) assay.25 The Myoglobin assay is based on the 
UV/vis detection of the conversion of deoxymyoglobin (deoxy-Mb) to carbonmonoxy-Mb 
(COMb). Mb serves as the oxygen transport protein in live muscles,26 but it has been 
established that it has a higher affinity for CO than it does for O2.27 During the assay, Mb is 








Deoxy-Mb absorbs at 557 nm and therefore exhibits a single maxima at this point in the 
UV/vis spectrum. In the presence of CO, deoxy-Mb preferentially binds to CO and is therefore 
converted to COMb. COMb has two absorbance maximums at 544 nm and 570 nm. This 
conversion and therefore the change in the electronic absorption spectra can be observed 
over time.  
Manganese and rhenium carbonyl complexes are often used to form cationic species to add 
various substituents in place of one of its ligands. These complexes have been studied for 
Scheme 3.1. Reduction, oxidation and addition of CO onto myoglobin. 
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their ability to take part in agostic C-H interactions,28,29 for the functionalisation of  
[ReX(CO)3(N-N)] complexes,30 and to synthesise luminescent manganese complexes.20,31 
Developing a method for the synthesis of a cationic species of the manganese complexes 
reported herein will be useful for future work. Manganese complexes are not inherently 
luminescent and cannot be visualized intracellularly. Through salt metathesis, fluorescent 
ligands can be added to the complex potentially rendering the complexes fluorescent.  
In this chapter, the synthesis and characterisation of two manganese and rhenium tricarbonyl 
complexes are reported. The reactivity of one manganese complex was evaluated via salt 
metathesis in order to attempt to synthesize a cationic manganese complex with two N-donor 
ligands: isoniazid and 4-picoline. The manganese complexes were further evaluated for their 
photochemical properties using IR spectroscopy, UV/Vis and a Myoglobin assay.  
 
3.2. Synthesis and characterisation of Quinoline-1,2,3-triazole 
Mn(I) and Re(I) tricarbonyl complexes  
3.2.1. Synthesis 
 
New Mn(I) and Re(I) complexes, Mn-1 and Re-1 were synthesised under similar conditions 
using a modified literature method where similar compounds were synthesised.1 The ligand 
L1 was reacted with either [MnBr(CO)5] or [ReCl(CO)5] as shown in Scheme 3.2 to afford either 
an orange or yellow powder in good yields of 93% (Mn-1) and 84% (Re-1). Due to the known 
photosensitivity of most Mn(I) tricarbonyl complexes and potential photosensitivity of their 














The chelation of the bidentate ligand L1 occurs via a dissociative substitution method,32 
similar to that of an SN1 reaction in organic chemistry. Initially, the halide atom acts as a cis-
labilizing ligand,33 allowing for the dissociation of a carbonyl cis to the bromide (cis-CO) and 
the subsequent association of either the imine or pyridyl nitrogen forming a 16-electron 
[MnBr(CO)4L1] intermediate as shown in Equation 3.1. With one nitrogen atom already 
complexed to the metal centre, it becomes easier for the second nitrogen atom to displace 
another CO and coordinate to the metal (Equation 3.2).  
 
[MnBr(CO)5] + L2 →   [MnBr(CO)4L2] + CO                                                          . . . . . Eqn 3.1 
[MnBr(CO)4L2]  →   [MnBr(CO)3L2] + CO                                                               . . . . . Eqn 3.2 
 
Imine and pyridyl nitrogens are both weaker π-acceptors than CO and are therefore likely to 
once again labilize a cis-CO as opposed to a trans one,33 resulting in the formation of a fac-




Scheme 3.2. Reaction scheme for the synthesis of Mn-1 and Re-1. Reagents and conditions: 
(i) [MnBr(CO)5], DCM, rt, 72 h. (ii) [ReCl(CO)5], DCM, 40 ℃ 96 h. 
  







Transition metal complexes can form two kinds of geometric isomers, either cis/trans isomers 
or fac/mer isomers. Cis/trans isomers refer to the spatial arrangement of two species whereas 
fac/mer refers to the spatial arrangement of three species. As previously mentioned, the cis-
effect of the bromide results in the formation of the cis-isomer with regards to L1. In turn, this 
effect resulted in the formation of the fac- as opposed to the mer-isomer with regards to the 
attached carbonyls, which will be confirmed in Section 3.2.2.2. 
 
3.2.2. Characterisation 
3.2.2.1. 1H and 13C{1H} NMR spectroscopy of Mn-1 and Re-1 
 
The 1H NMR spectrum of Mn-1 (Figure 3.3) shows a shift from 8.77 ppm (in ligand L1) and 
8.70 ppm to 9.22 ppm and 8.87 ppm for the pyridyl (H-1) and the imine (H-6) protons 
respectively.   Spectroscopic analysis of metal complexes and their parent ligand indicates that 
upon metalation, the synergic effect causes the resonance of protons on the carbon adjacent 
to the nitrogens to undergo upfield shifts. This synergic effect is caused by the donation of 
electrons from a filled π-orbital of the ligand to an empty metal orbital. Electrons are 
synergistically back-donated from a filled d-orbital of the metal centre into an empty π*-
antibonding orbital of the ligand.34 This back-donation has a shielding effect on protons 
surrounding the atom receiving to which electrons are back-donated, resulting in an upfield 
shift of the directly affected protons. 
 
Figure 3.2. Representative structure of the fac-[MX(CO)3L1] complex 
  














However, carbonyls are better π-acceptors than nitrogen, causing a stronger back-donation 
of electrons into C=O (Figure 3.4) rather than N=CH, deshielding protons H-1 and H-6. 

































Figure 3.3. Stacked 1H NMR spectra of L1, Mn-1 and Re-1 in DMSO-d6 
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The same characteristic downfield shifts of protons H-1 and H-6 are seen in the 1H NMR 
spectrum of Re-1. The chemical shifts of protons H-1 and H-6 shift from 8.77 ppm and 8.70 
ppm (L1) to 9.07 ppm and 9.31 ppm respectively. These downfield shifts are expected, due to 
the better π-accepting capacity of the CO ligands as explained for complex Mn-1. These shifts 
confirm that the bidentate ligand chelates to the metal centre via the pyridyl and amine 
nitrogens. All aromatic protons on the pyridyl and phenyl ring undergo a slight downfield shift 
as well, further confirming successful complexation. L1 chelates to the Re centre in a cis-
configuration with facially arranged carbonyls as described in for the Mn analogue.  The 13C 
{1H} NMR spectrum of Mn-1 has three singlets of low intensity at 222.22 ppm, 221.18 ppm 
and 218.3 ppm, corresponding to the three carbonyl carbons. There are three singlets of low 
intensity at 197.73 ppm, 197.19 ppm and 187.81 ppm, corresponding to the three carbonyl 
carbons in the 13C{1H} NMR spectrum of Re-1.  
 
3.2.2.2. IR spectroscopy of Mn-1 and Re-1 
 
The IR spectrum of Mn-1 and Re-1 (Figure 3.5) both show absorption bands of strong intensity 
for the CO ligands at 2024 cm-1 and 2019 cm-1respectively. Broad absorption bands with a 
shoulder are seen at 1914 cm-1 and 1886 cm-1 in the IR spectra of complexes Mn-1 and      Re-
1 respectively, corresponding to two CO ligands. These wavenumbers appear in the range 
common to facially arranged carbonyls suggesting that the three carbonyls lie on one face of 
the proposed octahedral geometry.35 The imine C=N band shifts to a lower wavenumber from 
1623 cm-1 in the ligand to 1610 cm-1 in  complex Mn-1, overlapping with that of the quinoline 
C=N absorption band. This was unexpected and contradicts the downfield shift observed for 
the imine proton in the 1H NMR spectrum. If back-donation were directed towards the imine 
C=N, the bond length would increase. This increase in bond length and decrease in bond order 
would result in a shift in the frequency of the C=N absorption band to a lower wavenumber 
and what is observed would be expected. However, back-donation is directed towards the 
carbonyls due to them being better π-acceptors. No similar examples of this occurrence were 
found in literature and further experiments will need to be performed to explain it. The 
pyridine C=N band shifts from 1595 cm-1 to a higher wavenumber of 1598 cm-1 in complex 
Mn-1. In the IR spectrum of Re-1, the imine C=N band shifts from 1623 cm-1 to 1614 cm-1, 
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overlapping with that of the quinoline C=N band. The pyridyl C=N band shifts from 1595 cm-1 














3.2.2.3.  Mass Spectrometry  
 
Complexes Mn-1 and Re-1 were analysed using high-resolution ESI-MS. The mass spectrum 
of Mn-1 shows the protonated molecular ion peak at m/z 660.9620 attesting to the integrity 
of the complex, correlating with the calculated value of 660.7680. A protonated molecular 
ion peak was observed at m/z 747.0309 in the mass spectrum of Re-1, corresponding with 


















Quinoline, pyridyl and 
imine C=N  
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3.3.      Synthesis and characterisation of aminoquinoline-1,2,3-
triazole Mn(I) and Re(I) complexes 
3.3.1.  Synthesis  
 
The ligand L2 was reacted with either [MnBr(CO)5] or [ReCl(CO)5] under the conditions shown 
in Scheme 3.3, to afford the new metal tricarbonyl complexes Mn-2 and Re-2. Mn-2 was 
isolated as an orange powder in a good yield of 70%. Re-2 was isolated as a yellow powder 
comprised of some unreacted ligand and the desired complex in a yield of 73%. L2 was reacted 
with [ReCl(CO)5] under several conditions, optimizing for solvents, equivalents of [ReCl(CO)5], 












Attempts to separate unreacted L2 from Re-2 were challenging, as both compounds were 
soluble in the same organic solvents and thus using recrystallisation/ trituration was 
unsuccessful. Both L2 and Re-2 displayed the same Rf value on silica TLC plates despite using 
varying mobile phases which included MeOH/DCM and EtOAc/petroleum ether. It was 
therefore not feasible to employ column chromatography.  It should also be noted that L2 
produced multiple spots on silica TLC plates, due to possible degradation of the imine. Further 
attempts to purify Re-2 were not explored and, instead, the focus was shifted to attempting 
to synthesize a cationic Mn(I) species. 
 
Scheme 3.3. Synthetic scheme for the synthesis of Mn-2 and Re-2. Reagents and conditions: 
(i) [MnBr(CO)5], DCM, 25 ℃, 24 h. (ii) [ReCl(CO)5], DCM, 40 ℃, 24 h. 
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3.3.2. Characterisation 
3.3.2.1. 1H and 13C{1H} NMR spectroscopy 
 
The 1H NMR spectra of Mn-2 and crude Re-2 are shown in Figure 3.6. Proton resonances of 
H-1 and H-6 undergo the expected downfield shifts from 8.69 ppm and 8.60 ppm (in L2) to 
9.22 ppm and 8.87 ppm respectively in the spectrum of Mn-2. H-8 and H-9 resonate downfield 
at 7.22ppm and 7.56 ppm respectively. Protons H-3, H-4 shift downfield and resonates in the 
same region as H-24. This results in a multiplet that integrates for three protons in the range 
























Figure 3.6. Stacked 1H NMR spectra of L2, Mn-2 and crude Re-2. The asterix (*) represents 
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In the 13C{1H} NMR spectrum of Mn-2, three carbonyl carbon signals are observed as low-
intensity singlets at 222.33 ppm, 221.22 ppm and 219.25 ppm. C-13 appears at 124.72 ppm, 
C-1 at 153.69 ppm and C-6 at 167.85 ppm. 
The 1H NMR spectrum of crude Re-2 sample does attest to successful chelation of L2 via the 
imine and pyridyl nitrogens to form Re-2. Upon complexation, protons H-1 and H-6 shift 
downfield to 9.06 ppm and 9.29 ppm respectively. H-9 and H-8 appear as doublets at 7.57 
ppm and 7.25 ppm respectively. Proton signals corresponding to unreacted L2 are indicated 
with an Asterix (*) and analysis of the ligand to complex ratio using 1H NMR spectroscopy 
indicates that there is a 0.5/1 ratio of ligand/complex.  
 
3.3.2.2.  IR spectroscopy 
 
A sharp strong absorption band is observed at 2024 cm-1  and 2019 for one carbonyl in the IR 
spectra of complexes Mn-2 and Re-2 respectively (Figure 3.7). A broader strong band is 
observed at 1914 cm-1 and 1889 cm-1for two carbonyls in the IR spectrum of Mn-2 and Re-2 
respectively. The range of these wavenumbers confirms that the fac-isomer has been 
synthesised. The imine C=N absorption band appears as a weak sharp absorption band at  
1603 cm-1 and the pyridyl C=N absorption band has not shifted, still residing at 1592 cm-1 in 





















3.3.2.3.  Mass spectrometry 
 
Mn-2 was analysed using high-resolution ESI-MS. The mass spectrum of Mn-2 shows a 
[M+MeCN+Na]+ peak corresponding to the molecular ion plus acetonitrile and a sodium 
molecule at m/z 736.4257 correlating with the calculated value of 736.4400. The Mass 
spectrum of Re-2 was not obtained, due to the known presence of L2 in the sample. 
 
3.4. Reactivity studies of complex Mn-1 using a [2+1] 
approach 
 
Reactivity studies were done using complex Mn-1 in an attempt to synthesize a cationic 
manganese species that could potentially be further functionalized. The method used for the 
[2+1] reactivity studies was a salt metathesis. Mn-1 has an N-N-bidentate ligand chelating to 
the metal centre, hence 2 and a single N-donor ligand will subsequently be attached, 
representing the 1 in [2+1]. Salt metathesis involves a halogen abstraction,36 and exchange 

























Figure 3.7. Stacked IR spectra of compounds L2, Mn-2 and Re-2. 
C=O  
Quinoline, pyridyl 
and imine C=N  
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The Mn complexes reported herein cannot be tracked intracellularly.The purpose of the 
reactivity study was to develop a method in which the bromide can be extracted from the 
metal centre and a simple N-donor ligand added in its place. This method could then be 
followed in future to add a fluorescent ligand such as dansyl imidazole,20 to potentially allow 
the compound to be visualized intracellularly.  
3.4.1. Attempted synthesis of cationic Mn-1 complex 
 
A [2+1] synthetic approach was followed whereby a halogen abstraction from complex Mn-1 
was conducted using AgCF3SO3. An N-donor was then added to the reaction mixture. The 
intermediate was either isolated as the triflate complex or underwent a counterion exchange 















Scheme 3.4. Synthetic routes taken for the attempted synthesis of cationic Mn-1. See Table 
3.1 for conditions i-vi.  
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Several reaction conditions were used to synthesize and isolate a cationic Mn-1 species 
substituted with two different N-donors: isoniazid or 4-picoline. These reaction conditions are 
outlined in Table 3.1.  These N-donors were chosen based on availability, 4-picoline was used 






3.4.2. Attempted synthesis and characterisation of [Mn-1(isoniazid)](CF3SO3/PF6) 
 
Isoniazid was used as an N-donor in the [2+1] reaction of complex Mn-1 with silver triflate 
(AgCF3SO3), however, the purification of the [Mn-1(isoniazid)](CF3SO3)/PF6) complexes were 
challenging. Analysis of the 1H NMR spectra of these complexes pointed to their possible 
synthesis. It was challenging to isolate the complexes from the impurities that were present. 
Mn-1 was reacted with AgCF3SO3 via a halogen abstraction and isoniazid was subsequently 
added under two different conditions, outlined in Table 3.1. Condition iv involved a 
counterion exchange reaction with NH4PF6. 
 
 










i MeCN AgCF3SO3 1.1 isoniazid 1.1 4 h 
DCM 20 h 
ii MeCN AgCF3SO3 2 isoniazid 2 22.5 h 
iii MeCN AgCF3SO3 2 4-picoline 2 22.5 h 
iv MeCN AgCF3SO3 2 isoniazid 2 2.5 h 
MeOH:DCM NH4PF6 2 20 h 
v MeCN AgCF3SO3 2 4-picoline 2 2.5 h 
NaBAr4F 1.3 20 h 
vi MeCN AgCF3SO3 2 4-picoline 2 2.5 h 
NaB(Ph)4 1.3 22 h 
Table 3.1 Optimisation of the synthesis of cationic Mn-1 
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3.4.2.1. 1H NMR spectroscopy 
 
The 1H NMR spectrum of [Mn-1(isoniazid)](CF3SO3) (Figure 3.8)  alludes to the synthesis of 
the complexes under both conditions i and ii. There is a downfield shift of the signal identified 
as H-1 from 9.22 ppm in Mn-1 to 9.39 ppm in the spectra of both cationic species. Proton 
resonances for H-a, H-b and NH are observed but due to the poor resolution, cannot be 
identified with absolute clarity. A cation exchange between CF3SO3 and PF6 yielded a more 
resolute spectrum, but the presence of multiple additional aromatic signals are observed in 
all three spectra. These peaks do not correlate to any of the starting material and suggest the 
possible formation of side products. Pike and co-workers compared various methods in which 
arenes and heteroarenes can be reacted with [MnBr(CO)5] to form [MnBr(CO)3]+ species.37 
They found that highly electron-deficient aromatics or aromatics containing electron-
withdrawing groups do not metalate at all or do so to a small degree. They also found that 
















[Mn-1(isoniazid)](CF3SO3)- Conditions i 









Figure 3.8. Stacked 1H NMR spectra of Mn-1, [Mn-1]isoniazid(CF3SO3)-conditions i, [Mn-1] 
isoniazid (CF3SO3)- conditions ii and [Mn-1]isoniazid(PF6) 
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This may explain the reluctance of isoniazid to react with Mn-1 under three different 
conditions. Although metalation does occur to a certain degree, the reaction does not appear 
to go to completion with the possible formation of side products.  Isoniazid contains the highly 
electron-withdrawing amide functional group, which may hinder metalation as described by 
Pike and co-workers.37 The [Mn-1(CO)3]+ is electron-deficient and the likelihood of 
coordination depends on the degree to which the N-donor donates its electrons.  
 
3.4.3. Synthesis and characterisation of [Mn-1(4-picoline)](Y) 
 
Due to the difficulty in isolating the cationic species from unreacted Mn-1, numerous 
inorganic salts were used in the hopes of generating a cationic complex that could easily be 
separated from Mn-1.  A simpler N-donor (4-picoline) was also used to determine if the amide 
functionality of isoniazid hinders the reaction. Mn-1 was reacted with AgCF3SO3 in MeCN to 
undergo a halogen abstraction, after which 4-picoline was subsequently added. The product 
was either isolated as the triflate species or a counterion exchange was done using NaBAr4F 
or NaB(Ph)4.  
3.4.3.1. 1H NMR spectroscopy 
 
Comparison of the 1H NMR spectra of [Mn-1(4-picoline)](BArF4) and [Mn-1(4-
picoline)](B(Ph4)) shows that synthesis of both cationic Mn-1 species does occur.  In both 
spectra, the diagnostic downfield shifts of H-1 and H-6 are observed. In the 1H NMR spectrum 
of [Mn-1(4-picoline)](BArF4), the methyl (CH3) protons signal is observed as a singlet at 2.35 
ppm. Aromatic protons belonging to 4-picoline can be identified, as indicated in Figure 3.9. 
The BAr4F aromatic protons H-d appear as a broad signal at 7.73 ppm, integrating for eight 

























Proton signals in the 1H NMR spectrum of [Mn-1(4-picoline)](B(Ph)4) are less distinguishable 
than seen in the spectrum of the BAr4F or CF3SO3 analogues. The ortho-H(BPh4) appears as a 
broad signal at 7.17 ppm, the meta-H(BPh4) appears as a triplet at 6.92 ppm and the para-
H(BPh4) appears as a triplet at 6.78 ppm. The methyl protons appear as a singlet at 2.33 ppm, 
but the 4-picoline aromatic signals cannot be identified. [Mn-1(4-picoline)](CF3SO3) produced 
the more resolute 1H NMR spectrum. The methyl protons are observed as a singlet at            
2.35 ppm, the H-1 doublet occurs at 9.31 ppm and the H-6 singlet appears at 9.00 ppm. H-a 
of 4-picoline is identified as the doublet at 8.39 ppm and H-b as the doublet at 7.35 ppm. The 
multiplicity of H-a and integration of both proton signals do not correlate to the structure of 






















Figure 3.9. Stacked 1H NMR spectra of Mn-1, [Mn-1(4-picoline)](CF3SO3), [Mn-1(4-
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Mn-1 is identified by the asterix (*). The use of larger inorganic salts did not simplify 
purification, despite attempts to purify using recrystallization, water-washing, column 
chromatography and Preparative Thin Layer chromatography. 
4-Picoline is more strongly electron-donating in comparison to isoniazid and should, 
therefore, complex with ease, which was indeed observed. Comparing the numerous 
inorganic salts used reveals a trend; Non-coordinating or weakly coordinating anions such as 
PF6, BAr4F and BPh4, produced 1H NMR spectra with signals that do not correspond to any of 
the starting materials or expected products. The triflate (CF3SO3) anion is slightly coordinating 
compared to the other anions used and may, therefore, form a more stable intermediate, 
allowing for metathesis to occur easier. 
 It is clear that the formation of the cationic species does occur under all conditions but the 
use of silver triflate and 4-picoline  produced a comprehensive 1H NMR spectrum with 
diagnostic peaks of the expected product. The general purification method used in literature 
for cationic manganese complexes is recrystallisation. However, this method was 
unsuccessful for the cationic Mn-1 species synthesised herein. Purification via 
recrystallization was unsuccessful, despite the use of several polar and non-polar solvents at 
various room temperatures. The synthesis of cationic [Mn-1(4-picoline)](CF3SO3) but 
difficulty in purifying the complex prompted further investigation using a simpler neutral 
complex as a starting material. 
 
3.4.4. Synthesis and characterization of a cationic pyridyl Mn complex  [Mn-4(4-
picoline)](CF3SO3/PF6) 
 
In order to identify any structural hindrance caused by the large size of complex Mn-1, a 
simpler system was employed to find an alternate route of synthesis and purification. The aim 
of this was to establish a method for the synthesis of a cationic manganese complex of the 
structurally smaller precursor compounds 1 and 2. Once a method is established for the 
simpler system, it could potentially be replicated using the larger complex Mn-1. 
Complexation was attempted using compounds 1 and 2  (discussed in Chapter 2)  to 
subsequently form the cationic species thereof, as shown in Scheme 3.5. Complexation of 
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compound 2 was not successful despite reacting 2 with [MnBr(CO)5] at room temperature nor 
upon refluxing for 24 or 72 hours. Compound 1 was therefore reacted with [MnBr(CO)5] to 






















Scheme 3.5. Synthetic routes taken for the attempted synthesis of Mn-3 and cationic [Mn-
4(4-picoline)](CF3SO3)and the synthesis of  Mn-4 and [Mn-4(4-picoline)](PF6). Reagents and 
conditions: (i) K2CO3, 18-crown-6, acetone, propargyl bromide, reflux, 72 h. (ii) [MnBr(CO)5], 
DCM, reflux, 24/72 h. (iii) [MnBr(CO)5], MeOH, reflux, 24 h. (iv) a) MeCN, AgSF3SO3, 2.5 h, b) 
4-picoline, 20 h. (v) a) DCM, AgPF6, 18 h, b) 4-picoline, 48 h. 
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3.4.4.1. 1H NMR spectroscopy 
 
In the 1H NMR spectrum of Mn-4 (Figure 3.10) the H-1 doublet and H-6 singlet have both 
shifted downfield from 8.67 ppm and 8.58 ppm in 1 to 9.88 ppm and 8.79 ppm respectively, 
confirming successful complexation. The hydroxyl proton is observed as a broad signal at    
9.88 ppm. All aromatic protons experience the electron back-donation towards the carbonyls, 
as all shift slightly downfield.  
Upon reaction of Mn-4 with AgCF3SO3 and 4-picoline, the 1H NMR spectrum shows clear 
upfield shifts in the proton resonances of H-1 and H-6 to 9.39 ppm and 8.89 ppm. The 4-
picoline proton resonances are observed at 7.99 ppm for H-a and 7.31 ppm for H-b. These 
shifts suggest successful metathesis, but as was observed for the cationic Mn-1 species, the 
resolution of the spectrum is poor. A second salt metathesis method was attempted whereby 
Mn-4 was reacted with AgPF6 following a literature method for a different complex,38 as 
shown in Scheme 3.5. In the 1H NMR spectrum of [Mn-4(4-picoline)](PF6) the H-1 doublet and 
H-6 singlet appear at 1.93 ppm and 8.89 ppm. 4-Picoline protons H-a appears as a doublet at 
7.99 ppm, H-b as a doublet at 7.33 ppm and the methyl protons as a singlet at 2.30 ppm 
integrating for three protons. The resolution of the 1H NMR spectrum is far better than 
observed for the triflate derivative and all protons are accounted for with the expected 
downfield shifts and presence of 4-picoline proton signals. Thus, using compound 1 as a ligand 
for complexation and the subsequent complex Mn-4 provides an easy method for the 























3.4.4.2. IR spectroscopy  
 
In the IR spectrum of Mn-4, the imine C=N absorption band is observed at 1604 cm-1 and the 
pyridyl C=N absorption band at 1591 cm-1. A sharp strong band is seen at 2027 cm-1 in Figure 
3.11, corresponding to one carbonyl. A strong absorption broad band is seen at         1918 
cm-1 with a shoulder and corresponds to two carbonyl functionalities. The range in which 





















Figure 3.10. Stacked 1H NMR spectra of compound 1, Mn-4, [Mn-4(4-picoline)](CF3SO3) and 
[Mn-3(4-picoline)](PF6) 
















Upon the formation of the cationic [Mn-4(4-picoline)](PF6) complex, the carbonyl bands shift 
to higher wavenumbers at 2036 cm-1 and 1926 cm-1. The cationic nature of the metal centre 
reduces the back-donation to the carbonyls. The imine and pyridyl C=N absorption bands also 
shift to higher wavenumbers at 1622 cm-1and 1595 cm-1 respectively.  
 
3.4.5. Synthesis and characterisation of [Mn-1(4-picoline)](PF6) 
 
As a consequence of the successful synthesis of [Mn-4(4-picoline)](PF6) using the reaction 
conditions outlined in Scheme 3.6, these conditions were replicated in the attempted 
synthesis of the quinoline-containing [Mn-1(4-picoline)](PF6) complex as shown in Scheme 


































Figure 3.11. Stacked IR spectra of Mn-4 and [Mn-4(4-picoline)](PF6) 
  








3.4.5.1. 1H NMR spectroscopy 
 
The 1H NMR spectrum of [Mn-1(4-picoline)](PF6) (Figure 3.12) shows the distinctive 
downfield shifts in proton resonance of H-1 and H-6 to 9.40 ppm and 8.96 ppm. The methyl 
protons are observed as a singlet at 2.32 ppm. H-a appears as a triplet at 8.43 ppm and H-b 
at 7.24 ppm. The resolution of the peaks is poor with unidentified peaks present in the 
aromatic region. These peaks do not correlate to any of the starting material and once again 
suggests possible decomposition of the product. The downfield shifts in the discussed proton 
resonances and the presence of 4-picoline proton signals indicate that the reaction was 
partially successful. Due to the higher success of using the triflate salt, the method which 














Figure 3.12. 1H NMR spectrum of [Mn-1(4-picoline)](PF6) 
Scheme 3.6. Synthetic route for the attempted synthesis of cationic [Mn-1(4-picoline)](PF6) 
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Thus, the method used to synthesise [Mn-4(4-picoline)](PF6] could not be used to isolate a 
pure cationic Mn-1 species.  
 
3.4.6. A brief summary of attempted synthesis of a cationic Mn(I) species 
 
In summary, several synthetic pathways were followed in an attempt to synthesize a cationic 
manganese complex. Two different N-donor ligands were used, isoniazid which contains an 
electron-withdrawing amide functionality and 4-picoline which contains the more electron-
donating methyl group.  The difficulty at which isoniazid reacted under the salt metathesis 
reaction conditions is determined by Pike et al. who found that electron-deficient aromatics 
do not perform well in these reactions.37 The use of various anions for the salt metathesis 
reactions revealed a trend in which the more coordinating anion CF3SO3 performed better 
under the reaction conditions than the less coordinating anions. The use of the smaller pyridyl 
phenol complex Mn-4 allowed for the successful synthesis of a cationic [Mn-4(4-
picoline)](PF6) complex. The same method used to synthesize the cationic Mn-4 complex 
could not be replicated to successfully synthesize [Mn-1(4-picoline)](PF6).  
 
3.5. Photochemistry of Mn(I) complexes 
 
Manganese tricarbonyl complexes are well-known for their photosensitive properties and 
their ability to release CO upon exposure to light. It is necessary to evaluate the 
photochemical properties of the synthesised compounds to establish their photosensitive 
wavelength and the degree of CO-release. The CO-releasing properties of complexes Mn-1 
and Mn-2 were evaluated using infrared spectroscopy, UV/Vis spectroscopy and a Myoglobin 
assay for Mn-1. The Re analogues did not express the same photo-dissociative properties as 
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3.5.1. Solution dark stability and CO-release of Mn-1 and Mn-2 
3.5.1.1. Electronic Absorption  
 
The absorbance maxima of complexes Mn-1 and Mn-2 were determined in a solution of 
DMSO and PBS buffer (pH 7.4) (5:95% ν/ν). Complexes Mn-1 and Mn-2 display two broad 
bands at ~240 nm and ~365 nm for the intraligand charge transfer (ILCT) and the metal to 
ligand charge transfer (MLCT) bands (Figure 3.13). These bands were assigned based on N-N-












The MLCT band provides the wavelength at which these complexes are most likely to release 
CO and thus the CO-release studies were done using light of 365 nm. Upon photodissociation 
of the carbonyls, the intensity of the MLCT bands are expected to decrease indicating that CO 
is being released. 
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3.5.1.2. CO-release using infrared spectroscopy 
 
To gain further insights into the CO-release properties from complexes Mn-1 and Mn-2, the 
spectral changes upon irradiation of solutions of these complexes in DCM were investigated. 
Solution state Infrared spectroscopy was used to evaluate photo-induced CO-release from 
complexes Mn-1 and Mn-2. Complexes Mn-1 and Mn-2 were dissolved in DCM and an IR 
spectrum was obtained at time zero (Figure 3.14). The solution was then irradiated with light 
of 365 nm in 30-minute increments after which an IR spectrum was recorded. The carbonyl 
absorption bands are seen at 2030 cm-1, 1945 cm-1 and 1925cm-1 for Mn-1. In the IR 
spectrum of complex Mn-2, the carbonyl absorption bands are observed at 1463 cm-1, 1379 
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Mn-1 Mn-2 
Figure 3.14. IR Spectral changes in the carbonyl region of complexes Mn-1 (left) and Mn-2 
(right) in DCM upon irradiation of 365 nm. 
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Upon irradiation of solutions of complexes Mn-1 and Mn-2 in DCM, the carbonyl absorption 
bands at their respective wavenumbers decrease in intensity (Figure 3.14). No intermediate 
carbonyl species can be observed. After 150 and 180 minutes of irradiation, the carbonyl 
bands can no longer be seen in the spectra of complexes Mn-1 and Mn-2 respectively. This 
suggests that the rate of CO-release is slower for complex Mn-2 compared to that of Mn-1, 
although no kinetic studies have been done as part of this study. The disappearance of the 
carbonyl absorption bands in both spectra is indicative of the structural changes these 
complexes undergo upon irradiation. As a consequence of the structural changes that occur, 
both solutions of complex Mn-1 and Mn-2 in DCM change colour from bright orange to brown 
upon prolonged exposure to light.  
The possible photosensitivity of Re-1 was evaluated following the same method used for the 
manganese complexes. Re-1 did not display photodissociation of its carbonyls upon 
prolonged exposure to light at 365 nm and natural daylight. This was confirmed using IR 
spectroscopy. 
 
3.5.1.3. Solution dark stability and CO-release  
 
It has been established that complexes Mn-1 and Mn-2 release CO in the presence of light, 
but it is necessary to investigate if they are stable in the dark. The CO-releasing properties of 
complexes, Mn-1 and Mn-2 were investigated using a Myoglobin assay. The Myoglobin assay 
is performed at 37 ℃ and makes use of DMSO/PBS as the medium, thus it is necessary to 
investigate the dark stability of the manganese complexes at body temperature in DMSO/PBS. 
Complexes Mn-1 and Mn-2 were dissolved in DMSO/PBS (pH 7.4) (5/95% ν/ν) and an 
electronic absorption spectrum of each solution was obtained at time zero. The mixtures were 
kept in the dark at 37 ℃ and an electronic absorption spectrum obtained every 1 hour for 6 
hours and after 24 hours.  
 
  









Both complexes Mn-1 and Mn-2 display long-term dark stability in DMSO/PBS (pH 7.4), as 
shown by the black spectra in Figure 3.15. Any changes seen in the spectra over 24 hours can 
be attributed to precipitation of the complex out of solution. The complexes were then 
irradiated at 365 nm in 1-minute, 2-minute and 5-minute increments over a 1-hour period. 
Irradiation was halted after each irradiation period to record an electronic absorption 
spectrum, shown by the red spectra in Figure 3.15. Upon irradiation, a distinct decrease in 
the absorption at the MLCT band is observed, indicative of photo-induced CO-release. This 
study shows that the complexes are stable in solution in the dark and releases CO only upon 
irradiation.  
The antiplasmodial activity of complexes Mn-1 and Mn-2 in the dark and upon photo-
excitation is evaluated in Chapter 4. The antiplasmodial activity was tested using a pLDH assay 
which makes use of DMSO and growth medium. Thus, to investigate the dark stability and 
photolysis behaviour of complexes Mn-1 and Mn-2 in a mixture of DMSO/growth medium 
(5/95% ν/ν), the complexes were incubated at 37 ℃ for 24 hours. An electronic absorption 
spectrum was recorded every 1 hour for 5 hours and after 24 hours (Figure 3.16, black 





























Figure 3.15. Electronic Absorption spectra of Mn-1 (left) and Mn-2(right) in DMSO and PBS 
(5/95% ν/ν) at 37 ℃. Stability over 24 hours (black) and irradiation of increasing time at 365 
nm (red).  
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minutes, after each irradiation period an electronic absorption spectrum was recorded 
(Figure 3.16 (left)). The Mn-2 solution was irradiated at 365 nm in 1-minute, 2-minute and 5-
minute increments for an hour. After each irradiation period, an electronic absorption 














Complexes Mn-1 and Mn-2 both show dark stability in a mixture of DMSO and growth 
medium over a 24-hour period, as shown by the black spectra in Figure 3.15. The MLCT bands 
are observed at higher wavenumbers in the growth medium. The broad MLCT bands are seen 
at 480 nm and 601 nm for Mn-1 and Mn-2 respectively. The solvent used in Ultraviolet-visible 
spectroscopy affects the wavelength at which the MLCT band is observed. The position of the 
MLCT band is related to the solvating ability of the solvent being used.  Upon irradiation of 
these solutions of complexes, the absorbance at the MLCT band of both complexes decreases 
in intensity, as seen by the red spectra. The release of CO occurs more rapidly for Mn-1 
compared to that of Mn-2, as after 5 minutes no MLCT band is observed in the electronic 




























Figure 3.16. Electronic Absorption spectra of Mn-1 (left) and Mn-2(right) in DMSO and growth 
medium (5/95% ν/ν). Stability over 24 hours (black) and irradiation of increasing time at 365 
nm (red).  
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the MLCT band is seen after 35 minutes. Comparison of Figures 3.15 and 3.16 suggests that 
the rate of CO-release is dependent on the medium in which the complex is in at the time of 
photolysis. It is clear that CO-release from both complexes Mn-1 and Mn-2 occurs faster in 
the DMSO/growth medium mixture than it does in the DMSO/PBS mixture.  
 
3.5.1.4. CO-release using the Myoglobin assay 
 
The Myoglobin assay allows for the detection and quantification of CO-release. The 
Myoglobin assay is the most widely used assay for the quantification and determination of 
the rate of CO-release. The assay is based on the UV/Vis detection of the conversion of deoxy-
myoglobin (deoxy-Mb) to carboxy-myoglobin (COMb). In the presence of CO, myoglobin 
irreversibly binds to CO, resulting in the formation of COMb. The source of CO comes from 
the complex which photo-actively releases CO, resulting in a change in the Q-band region of 











Myoglobin in PBS (0.01 M, pH 7.4) was reduced with a solution of sodium dithionite in PBS 
(0.01M, pH 7.4) and degassed by bubbling argon into the solution. A solution of complex Mn-
1 in DMSO (10 μM, 10 μL) was added and an initial electronic absorption spectrum was 
Figure 3.17. Visible spectra of Mb and COMb.39  
  
101 Chapter 3  Quinoline-triazole Mn(I) and Re(I) tricarbonyl complexes  
obtained, as shown in Figure 3.18. At time zero, only deoxy-Mb is present, as shown by the 
parabolically shaped spectrum with a maximum at 557 nm. The mixture was then irradiated 
at 365 nm in 1-minute increments for 10 minutes, 2-minute increments for 10 minutes and 
5-minute increments for the remainder of an hour. As irradiation proceeds, the absorbance 
at 557 nm shows a steady decrease while the absorbance at 544 nm and 577 nm increase 
rapidly. This is indicative of the conversion of deoxy-myoglobin to COMb, confirming that CO-














The concentration of COMb formed was determined via calculation using the molar extinction 
coefficient for COMb (15.4 mM-1 cm-1).25 A graph of [COMb] vs time was plotted and is shown 
in Figure 3.19.  The concentration of COMb increases over the irradiation period, plateauing 
at ca. 21.5 μM, after approximately 40 minutes of irradiation. A 10 μM solution of complex 
Mn-1 is used in the assay, indicating that on average, approximately 2 equivalents of CO 
molecules is released per Mn-1 molecule present. CORMS are able to release varying 
equivalents of CO per CORM present, as those synthesised by Brückmann et al.42 It is not 
Figure 3.18. UV/vis spectral changes in the Q-band region of myoglobin upon irradiation at 
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uncommon for Mn(I) tricarbonyl complexes to release fewer than three CO’s per molecule of 











The rate of CO-release is determined using the half-life (t1/2), defined as the time required for 
the complex to release half of the total CO-ligands present. The t1/2 needs to be less than two 
hours to produce a high enough concentration of CO intracellularly.18 CO-release is 1st order,43 
therefore, the half-life can be calculated by fitting a 1st order growth curve (Figure 3.19).  The 
equation for 1st order exponential growth can be seen in Equation 3.3. 
y = y0 + A1e
x
t1                                                                                                                     … . . Eqn 3.3 
[COMb] = y0 + A1e
t1/2






















Figure 3.19. Plot of [COMb] (μM) formation with increasing irradiation time at 365 nm for a 
solution of complex Mn-1 (10 μM)) in PBS (0.01 M, pH 7.4), myoglobin (60) and sodium 
dithionite (10 mM).  
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t1
2
=  t1 ln(
-y0
2A1
)                                                                                                                    … . . Eqn 3.6 
 
The concentration of COMb is plotted on the y-axis of Figure 3.19 and time on the x-axis, thus 
rearrangement of Equation 3.3 and substitution of the relevant values gives Equation 3.4. y0 
is the point at which the concentration starts to plateau, therefore at t1/2 the concentration 
of COMb equals half of y0, resulting in Equation 3.5. Rearrangement of Equation 3.5 to make 
t1/2 the subject of the formula gives Equation 3.6, of which the values are obtained from the 
graph in Figure 3.18. The CO-release t1/2 of complex Mn-1 was therefore calculated to be 
22.28 minutes, which is shorter than the threshold 2-hour period. This t1/2 is comparable to 
N-N-Mn tricarbonyl complexes reported in literature.42,44 
Berends et al. proposed the identity of the CORM photolyzed products,44 as shown in Scheme 
3.7. Upon photoexcitation, one Mn-CO bond is labilized (step 1) and a CO is released in step 
2. These two steps result in the formation of a manganese dicarbonyl species, which is verified 
in the IR spectrum shown in Figure 3.14. This is followed by the photo-release of the 
remaining CO-molecules, resulting in an oxidized Mn(II) species. The oxidation state of the 
photolyzed product can however only be confirmed by EPR spectroscopy and is therefore only 
a speculation based on literature at this point.42 The oxidizing agent is unknown and would 
need to be determined via further experiments. It can, however, be confirmed that O2 is not 
the oxidizing agent, as during the O2 free myoglobin assay CO is still released and COMb 
formed (step 5). Further studies into identifying the photolyzed products of this project will 
need to be conducted in the future.  
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3.9.  Summary 
 
Two new Mn(I) and Re(I) tricarbonyl complexes, based on a quinoline-1,2,3-triazole scaffold 
have been synthesised and characterised. Several attempts were made at salt metathesis 
using Mn-1 to synthesise a cationic species. It can be concluded that using an N-donor with 
an electron-withdrawing group (isoniazid) hinders the reaction. A suitable coordinating 
counterion results in the formation of a more stable product than a non-coordinating 
counterion. The method using AgCF3SO3 as the metal salt and 4-picoline resulted in the most 
resolute 1H NMR spectrum, but the isolation of [Mn-1(4-picoline)](CF3SO3) from unreacted 
Mn-1 was unsuccessful.  
Complexes Mn-1 and Mn-2 were further evaluated for their CO-releasing properties under 
various conditions and were found to be stable in both DMSO/PBS and DMSO/growth 
medium in the dark. Complexes Mn-1 and Mn-2 both release CO upon photo-excitation at 
365 nm in DCM, DMSO/PBS and DMSO/growth medium solutions. The rate of CO-release is 
medium dependent and Mn-1 releases CO faster than Mn-2. The standard Myoglobin assay 
was performed in the presence of complex Mn-1 in DMSO and CO-release was confirmed due 
Scheme 3.7. Proposed CO-release mechanism and photolyzed products.41  
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to the successful conversion of deoxy-Mb to COMb. Complex Mn-1 releases 2 equivalents of 
CO’s per CORM present, with 72.3% of the CO’s being released over the 1-hour period. The 
t1/2 was found to be 22.28 minutes, which was far below the 2-hour threshold period of 
efficient CO-release. It should be noted that complex Mn-2 produces an identified precipitate 
upon irradiation with a 32 W UV lamp. This precipitate was removed using a syringe filter 
before taking any spectroscopic readings. Re-1 did not express any photosensitivity under the 
tested conditions. 
The wavelength at which the manganese complexes release CO is not ideal for in vivo 
biological studies. Future work should involve red-shifting the CO-release to higher 
wavelengths around 700-800 nm. The higher wavelengths allow for the deeper skin 
penetration of the light and are also less damaging to DNA. It would be useful to perform 
kinetic studies to provide insight into the rates of CO-release so that if needed this could be 
improved on in the future. The identity of the photolyzed products is of great importance for 
biological use as well. Since the complexes are evaluated for their in vitro antiplasmodial 
activity in Chapter 4, it is essential to identify if the activity is solely due to the complex and 
CO-release or if the photolyzed products express any biological activity as well. 
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Chapter 4 
Antiplasmodial evaluation  
 
4.1.  Introduction  
 
During the blood stage of the malaria parasites life cycle, haemoglobin is ingested by the 
protozoan cytosome and transported into the parasite’s acidic food vacuole.1 The iron centre 
in haemoglobin undergoes oxidation,2 and is broken down into free heme and amino 
acids.3,4,5 When accumulated in high enough concentrations, heme is toxic and can cause 
early parasitic lysis.6 At these high concentrations, reactive oxygen species (ROS) are 
produced. These ROS cause the parasite to undergo “lipid peroxidation”, whereby the lipids 
in the membrane degrade resulting in parasitic death.5 The parasite has therefore developed 
a detoxification method, in which it converts heme into inert biocrystals known as hemozoin 
as shown in Figure 4.1.7 Hemozoin is a highly crystallized insoluble form of heme aggregates 
that is non-toxic to the parasite. 
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As mentioned in Chapter 2, chloroquine (CQ) and quinoline-comprising drugs have been 
mainstays in antimalarial chemotherapy. CQ is a blood schizonticidal drug and therefore only 
acts during the blood stage of the parasitic life cycle.8 CQ and its analogues work by preventing 
the formation of hemozoin, resulting in parasitic death. CQ is a weak base with pKa of 8.1 
(quinoline nitrogen) and 10.2 (diethylamine side-chain nitrogen), it enters into the acidic 
parasitic digestive vacuole (pH of 5-5.2) in its unprotonated form.8 Thus when entering into 
the DV, chloroquine becomes protonated, resulting in the accumulation of the drug in this 
form.9 CQ is able to inhibit the polymerization of free heme into hemozoin, increasing 
intracellular heme,10 as shown in Figure 4.2.11 The exact mechanism by which chloroquine 
and its analogues work is unknown.12 CQ-resistance in P.falciparum is conferred by the 
mutation in the pfCRT gene.13 PfCRT is an acronym for “Plasmodium falciparum Chloroquine 
Resistance Transporter”. Mutated PfCRT has the ability to transport protonated CQ out of the 
cell, preventing the accumulation of the drug and therefore resulting in CQ-resistance.14 
Figure 4.1. Proposed degradation of free heme to form non-toxic biocrystal hemozoin in 
acidic vacuole of the malaria paraste.1 
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HO-1 is an enzyme encoded by the gene Hmxo1. It has several protective properties,15 and is 
responsible for heme catabolism.16 HO-1 is produced at low levels in all cells but production 
thereof can also be induced by various stimuli including the presence of heme (which is 
produced in the presence of malaria).15 Pamplona and co-workers report that HO-1 inhibits 
the development of experimental cerebral malaria (ECM) in mice.17 ECM is a severe 
neurological complication of P.falciparum malaria.18 The prevention of pathogenesis 
expressed in the BALB/c mice was due to the higher expression of Hmox1. They then went 
onto to show that exposure to CO prevented ECM and death and therefore concluded that 
prevention is due to CO.17 It was found that exposure to CO does not prevent or change the 
level of parasitaemia, but rather prevents the onset of ECM.17 This serves as evidence that 
CORMs could be used to treat malaria, even though CO does not affect the level of 
parasitaemia in the conducted study. It is possible that treatment with a CORM which 
provides dual pharmacological effects, conferred by the pharmacological scaffold and CO-
releasing properties may result in notable antimalarial properties. 
Figure 4.2. Mechanism of action of CQ.11 
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In this chapter, we report the antiplasmodial activity of the synthesized quinoline-1,2,3-
triazole ligands and their respective Mn(I) and Re(I) complexes. The antimalarial activity of 
the Mn(I) tricarbonyl complexes is evaluated in the dark and upon irradiation to determine 
the effects of CO on the antimalarial activity. Subsequently, the mode of action of the 
compounds is determined using a β-hematin inhibition assay. 
 
4.2.  Antiplasmodial evaluation using pLDH assay 
4.2.1.  In vitro antiplasmodial activity (dark) 
 
Research on the antimalarial evaluation of manganese and rhenium tricarbonyl complexes is 
scarce. Therefore, it is worthwhile to investigate the antiplasmodial activity of the synthesized 
complexes. In vitro antiplasmodial activity is evaluated using a pLDH assay. Plasmodium 
lactate dehydrogenase (pLDH) is an enzyme secreted during the glycolytic pathway in the 
Plasmodium species, with species-specific isomers existing.19 The enzyme converts pyruvate 
to lactate using the cofactor NADH.20 The pLDH enzyme is representative of viable 
Plasmodium in the blood and disappears within 24 hours of effective treatment.21 The assay 
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The assay replaces NADH with the structurally similar APAD+, due to its ability to bind to pLDH 
more efficiently. During the assay, parasitic RBCs are present and pLDH oxidizes lactate to 
pyruvate and in turn, reducing the cofactor APAD+ to APADH. APADH reduces tetrazolium dye 
(nitroblue tetrazolium) to formazan,20 as shown in Scheme 4.1. The colour changes from 
yellow to blue and is indicative of cell viability.  
The in vitro antiplasmodial activity of compounds L1, L2, Mn-1, Re-1 and Mn-2 (Chapters 2 
and 3) were evaluated against the NF54-CQ-sensitive and K1-CQ-resistant strains of 
plasmodium falciparum. The 𝐼𝐶50 values of each compound were obtained at a concentration 
of 10 000 ng/mL and were compared to that of chloroquine diphosphate (CQDP), as shown in 
Table 4.1. 
 Ligand L1 was insoluble in DMSO at the tested concentration and therefore an 𝐼𝐶50 value 
could not be obtained. However, complexation improves the solubility of the ligand. 
Complexes Mn-1 and Re-1 show good antiplasmodial activity in the low micromolar range in 
both strains of P. falciparum. The 𝐼𝐶50 values of complexes Mn-1 and Re-1 in the NF54-CQ-
sensitive are 3.81 μM and 4.61 μM respectively. In the K1-CQ-resistant strain, the  𝐼𝐶50 values 
are 4.22 μM and 5.02 μM for complexes Mn-1 and Re-1 respectively. Complexes Mn-1 and 
Re-1 both retain their activity in the CQ-resistant strain, as they both have resistance indices 
of 1.1. CQ does not retain its activity in the CQ-resistant strain as indicated by the RI value of 
7.2. The antiplasmodial activity of the manganese analog is relatively similar to that of the 
rhenium. 
 Ligand L2 has 𝐼𝐶50 values of 0.33 μM and 0.69 μM in the CQ-sensitive and CQ-resistant strains 
respectively.  Complex Mn-2 has an 𝐼𝐶50 value of 0.54 μM in the CQ-sensitive strain and 1.16 
μM in the CQ-resistant strain. The ligand L2 expresses a 0.6- and 0.7-fold higher 
antiplasmodial activity than its manganese complex Mn-1 in the CQ-sensitive and -resistant 
strains respectively. The RI values of compounds L2 and Mn-2 are greater than 1 (2.1) but are 
still lower than CQDP. Therefore, both compounds L2 and Mn-2 do partially retain their 
activities in the CQ-resistant strain. 
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Table 4.1. In vitro antiplasmodial activity (dark) and resistance indices of compounds L1, Mn-
1, Re-1, L2, Mn-2and CQ against the NF54-CQ-sensitive and the K1-CQ-resistant strains of P. 
falciparum. 
a Resistance index = 𝐼𝐶50  (𝐶𝑄 − 𝑟𝑒𝑠𝑖𝑠𝑡𝑎𝑛𝑡)/ 𝐼𝐶50 (𝐶𝑄 − 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑒) 
bNot determined 
 
The 𝐼𝐶50 values obtained for Mn-2 are 7- and 4-fold lower than those obtained for Mn-1 in 
the CQ-sensitive and -resistant strains respectively. The presence of a basic amino-propyl 
chain, therefore, improves the antimalarial activity, as seen in the literature.22,23  Literature 
shows that including the 4-amino functionality improves the haematin binding ability of 






 (µM) ±SE 
 
  Dark 
   NF54 K1 RIa 
L1 
 
N/Db N/Db N/Db 
Mn-1 
 
3.81 ± 0.13 4.22 ± 0.21  1.1 
Re-1 4.61 ± 0.13 5.02 ± 0.14 1.1 
L2  0.33 ± 0.12 0.69 ± 0.425 2.1 





0.151 ± 0.00656 7.2 
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4.2.2.  Antiplasmodial evaluation upon irradiation (using a 32W UV lamp) 
 
The emergence of drug-resistant strains of P. falciparum poses the biggest malaria threat. It 
is thus essential to develop compounds that are active against the resistant strains of P. 
falciparum. The malaria parasite confers infection via the polymerisation of free heme into 
hemozoin and CO is known to prevent the oxidation of haemoglobin and formation of heme. 
Thus, CO presents a protective mechanism against malaria infection, as mentioned in Section 
4.1. Considering this, the in vitro antiplasmodial activity of complexes Mn-1 and Mn-2 were 
evaluated in the K1-CQ-resistant strain upon photo-induced CO-release. Two 94-well plates 
were simultaneously set up, the first was a control plate kept in the dark throughout the 
assay. The second was an experimental plate that was irradiated using a 32 W UV lamp for 30 
minutes. Complexes Mn-1 and Mn-2 were shown to release CO upon irradiation at 365 nm 
vide supra Chapter 3. The results of this experiment are shown in Table 4.2.  
  
Table 4.2. IC50 values of complexes Mn-1 and Mn-2 against K1-CQ-resistant strain of P. 
falciparum in the dark and upon irradiation at 365 nm for 30 minutes.  
 
a𝐼𝐶50 𝑟𝑎𝑡𝑖𝑜 𝐼𝐶50 𝑙𝑖𝑔ℎ𝑡/𝐼𝐶50 𝑑𝑎𝑟𝑘 
Compound Structure IC
50










6.72 ± 0.55 0.994 ± 0.87 0.14 
Mn-2  3.84 ± 3.03 1.41 ± 0.40 0.37 
CQDP 
 
0.134± 0.04 0.141± 0.009 1.05 
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The 𝐼𝐶50 value of complex Mn-1 decreases 7-fold from the dark (6.72 μM) to light irradiation 
(0.994 μM) as shown in Table 4.2. The 𝐼𝐶50 value of complex Mn-2 decreases 3-fold upon 
irradiation of 365 nm. The 𝐼𝐶50 value of CQ remains constant as shown by the 𝐼𝐶50 ratio of 
1.05. This indicates that CQ and the parasitic viability is unaffected by the UV itself. As 
mentioned in Section 4.1, CO confers protection against malaria, therefore, it is expected that 
upon CO-release, the antiplasmodial activity of the compound should increase.17 The 𝐼𝐶50 
ratios of complexes Mn-1 and Mn-2 are both below 1, attesting to the increased 
antiplasmodial activity induced upon CO-release. The 𝐼𝐶50 values of complexes Mn-1 and Mn-
2 in both the dark and light are not comparable to chloroquine. However, the increased 
efficacy of the drug induced upon CO-release suggests that the use of CORMs provides a 
promising method of combating drug-resistant P. falciparum. These antiplasmodial studies 
are preliminary and further studies are required. It is necessary to perform cytotoxic 
experiments to determine if the compounds affect healthy cells as well.  CO is a toxic gaseous 
molecule; it is essential to determine the localization of the compounds and concentration of 
CO intracellularly.  
 
4.3. Mechanistic studies: NP-40 Detergent-Mediated Assay 
for β-haematin inhibition 
 
Literature reports that β-haematin resembles hemozoin chemically, spectroscopically and 
crystallographically and is thus considered a synthetic form of hemozoin.5 Chloroquine is 
reported to inhibit β-haematin synthesis at physiological temperatures,25,26 as discussed in 
Section 4.1. Since the synthesized compounds contain a quinoline scaffold, it is necessary to 
evaluate if their mode of action resembles that of chloroquine.  An NP-40 detergent-mediated 
assay was used according to the method outlined by Sandlin et al.27 in order to determine if 
the synthesized complexes are β-hematin inhibitors. Compounds Mn-1, Re-1, L2 and Mn-2 
were evaluated for their β-haematin inhibition properties. The amount of synthetic heme was 
quantified using the colorimetric pyridine ferrochrome method developed by Egan and co-
workers.28 Pyridine does not complex to β-haematin, but does to free haem, allowing for the 
amount of synthetic hemozoin formed to be measured. This measurement was performed by 
recording the absorbance readings of each well in the 96-well plate.  
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The human body receives the majority of its iron (Fe) from the degradation of haemoglobin 
in the RBC.29 RBCs are phagocytized by macrophages and degraded in phagolysosomes, 
liberating haemoglobin. Haemoglobin is comprised of a heme group (made up of a porphyrin 
ring and central iron)30 and globins. The heme is oxidized by the enzyme heme oxygenase 
(heme-oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2)) and biliverdin reductase. In the 
presence of high heme concentrations, HO-1 is upregulated catalysing the catabolism of heme 
into biliverdin, Fe2+ and carbon monoxide,31 as shown in Scheme 4.2. Pamplona et al. 
reported that CO inhibits the degradation of haemoglobin into free heme.17 This subsequently 
























RBC degraded in 
phagolysosome  
Heme  
Prevents oxidation of 
Hb and subsequent 
generation of Heme 
Bilirubin 
Scheme 4.2. Haemoglobin degradation pathway in macrophage and haemoglobin 
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It can, therefore, be assumed that upon photoexcitation and induction of CO-release, the β-
hematin inhibition expressed by the complexes should increase. Thus, the β-hematin 
inhibition assay was performed simultaneously in both the dark and upon photoexcitation at 
365 nm. Figure 4.3 shows the dose-response curves obtained from the β-hematin inhibition 
assay in the dark and light. The curves of Mn-1, Re-1, L2 and Mn-2 in the dark indicate that 
the synthesized compounds mimic the expected sigmoidal shape seen for CQDP This shows 
that the ligand and complexes are all β-hematin inhibitors, with the synthesized complexes 
exhibiting a two-fold higher β-haematin inhibition compared to CQDP in the dark. L2 inhibits 
β-hematin to a lesser extent than all the synthesized complexes and CQ. This can be seen in 
Figure 4.3, as the dose-response curve representative of ligand L2 is shifted to the right of CQ 
and the complexes. The lower β-haematin inhibition displayed by L2 does not coincide with 
the higher antiplasmodial activity exhibited by the compound. This indicates that L2 may have 
a second mode of action that results in its higher antiplasmodial activity compared to the 
complexes. The β-haematin inhibition activity of compound Re-1 is slightly greater than that 
of both manganese complexes, as seen by the 𝐼𝐶50 values (Table 4.3) obtained from the log-
based dose-response curves in Figure 4.3. Both manganese complexes exhibit relatively 
similar levels of β-haematin inhibition in the dark. Thus, the presence of the amine and 3-C 
spacer improves the antiplasmodial activity but not the ability of the complex to inhibit β-




















Upon photoexcitation of complex Mn-1 for 30 minutes, the β-hematin inhibition increases 
significantly as indicated by the shift to the left of the dose-response curve in Figure 4.3 and 
the lower 𝐼𝐶50 value in Table 4.3. It can be assumed that the increase in inhibition is due to 
CO-release. It would be useful to use gaseous CO as a control in the future. After irradiation 
of 30 minutes, complex Mn-2 no longer takes on a sigmoidal shape. However, it should be 
noted that upon irradiation complex Mn-2 forms an unidentified precipitate that may 
interfere with the absorbance. It can therefore not be confirmed whether the β-hematin 

































Figure 4.3. Log-based dose-response curves for the β-hematin inhibition of compounds Mn-
1, Re-1, Mn-2, L2 and CQ in the dark and light. Complexes Mn-1 and Mn-2 were irradiated at 
365 nm with a 32 W UV lamp for 30 minutes prior to incubation. 
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Table 4.3. 𝐼𝐶50 values of compounds Mn-1, Re-1, Mn-2, L2 and CQ obtained from β-hematin 





The 𝐼𝐶50 values of CQ in the dark and light are 36.88 μM and 31.53 μM respectively.  This 
indicates that irradiation of 365 nm may influence one or more of the components used in 
the β-hematin assay. It should also be noted that the NP-40 Detergent-Mediated β-haematin 
inhibition assay is cell-free. While these synthesized compounds are β-hematin inhibitors 
under cell-free conditions, they may not exhibit the same mechanism of action intracellularly, 





Compound Structure IC50 (μM) ± SE   




14.53 ± 0.75 11.37 ± 0.60 
Re-1 13.48 ± 0.78 N/Aa 
L2  40.96 ± 1.05 N/Aa 
Mn-2  14.47 ± 0.53 N/Db 
CQDP 
 
36.88 ± 0.79 31.53 ± 1.76 
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4.4. Summary  
 
Two quinoline-1,2,3-triazole ligands and their respective manganese and rhenium tricarbonyl 
complexes were screened for their in vitro antiplasmodial activity against the NF54-CQ-
sensitive and K1-CQ-resistant strains of P. falciparum. Ligand L1 was not active at the tested 
concentration whereas its respective Mn (Mn-1) and Re (Re-1) complexes display good 
antiplasmodial activity, with 𝐼𝐶50 values in the low μM range. The Mn(I) and Re(I) analogues 
display similar activity with the Re-1 complex having a 0.2-fold higher 𝐼𝐶50 value than Mn-1 
in both strains of P. falciparum. Complex Mn-2 is 7- and 4-fold more active than Mn-1 in the 
CQ-sensitive and -resistant strains respectively. The addition of an amino-propyl improves the 
antiplasmodial activity of the synthesized compounds, as it has shown to do in the literature 
as well.22 The ligand L2 exhibits the highest antiplasmodial activity in both the CQ‐sensitive 
and ‐resistant strains respectively.  
The antiplasmodial activity of complexes Mn-1 and Mn-2 increase 7‐ and 3‐fold respectively 
in the K1‐CQ‐resistant strain upon photoexcitation at 365 nm. The increase in antiplasmodial 
activity exhibited upon light‐induced CO‐release presents a promising mechanism of 
combating drug‐resistant P. falciparum. These in vitro CO‐releasing studies of complexes Mn-
1 and Mn-2 paves the way for future studies. Although these studies are preliminary, the 
outcome shows that CO CORMs could potentially be used to enhance the antimalarial activity 
of a given compound. 
 All compounds (Mn-1, Mn-2, Re-1 and L2) showed β‐hematin inhibition properties, with 
complexes Mn-1, Mn-2 and Re-1 being greater inhibitors than CQ. Ligand L2 exhibited the 
greatest antiplasmodial activity between all tested compounds but showed the lowest β‐
hematin inhibition activity. Thus, further studies are required to determine the mechanism of 
action of ligand L2. Upon photo‐induced CO‐release, the β‐hematin inhibition of complex Mn-
1 increases drastically, whereas the dose‐response curve of complex Mn-2 no longer takes the 
expected sigmoidal shape. Due to the unknown identity of the photolyzed products of either 
of the complexes, the reason for the loss of β-hematin inhibition upon photoexcitation of 
complex Mn-2 cannot be predicted. The β-hematin inhibition assay is cell free and therefore 
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to confirm the proposed mechanism of action of the synthesized compounds, further studies 
are required.  
The CO‐release antiplasmodial studies are preliminary and further studies are required to 
conclude that the improved antiplasmodial activity is undoubtedly due to CO‐release. It is 
essential to identify the photolyzed products and if these products display any biological 
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Chapter 5 
Conclusion and Future outlook 
 
5.1.  Overall summary and conclusion 
 
The main objective of this study was to synthesize two new Mn(I) and Re(I) PhotoCORMs 
based on a quinoline-1,2,3-triazole scaffold and characterize the parent ligands and their 
complexes using various spectroscopic analysis which included NMR, IR, and mass 
spectrometry. The ligands and their respective metal carbonyl complexes were evaluated for 
their antimalarial and CO-releasing properties. To the best of our knowledge, the antimalarial 
evaluation of Mn(I) PhotoCORMs has not been reported in the literature.  
Two new quinoline-1,2,3,-tiazole compounds were synthesized using standard copper-
catalysed azide/alkyne cycloadditions (CuAAC) and characterized using the aforementioned 
spectroscopic techniques. The reactions proceeded in DCM with reaction times of 4 h for 
ligand L1 and 18 h for ligand L2. The yields of ligands L1 and L2 were only moderate but it was 
easy to purify and isolate these compounds once the reactions reached completion, in-line 
with the criteria defining “click” chemistry. Although DCM is not considered a “green” solvent, 
it is an easily removable solvent and therefore these reaction conditions partially follow the 
criteria of common “click” reactions.  
Complexation of ligands L1 and L2 to the metal precursors [MnBr(CO)5]/ [ReCl(CO)5] 
proceeded via a dissociative/ associative mechanism. This resulted in the synthesis of fac-
Mn(I) and -Re(I) tricarbonyl complexes with the ligands chelating through the pyridyl and 
imine nitrogens via a cis-conformation. The reaction conditions for complexation of each 
ligand to Mn and Re centres were specific to the ligand and metal centre. Re-2 was 
synthesized but attempts to separate the complex from unreacted ligand was unsuccessful. 
The synthesis of a cationic Mn-1 species was attempted using a salt metathesis method. Silver 
triflate was used in the halogen abstraction step with the addition of several metal salts for a 
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counterion exchange. A [2+1] approach was used in which the ligand representing the 1 was 
either isoniazid or 4-picoline. The most successful reaction conditions were the use of silver 
triflate and 4-picoline in MeCN, but purification of the desired product was unsuccessful. 
The ligands and metal complexes were evaluated for their in vitro antiplasmodial activity 
against the NF54-chloroquine-sensitive and the K1-chloroquine-resistant strains of 
Plasmodium falciparum (P. falciparum). All tested compounds show good antiplasmodial 
activity with 𝐼𝐶50 values in the low micromolar range. The manganese and rhenium analogues 
exhibit similar antiplasmodial activities and retain their activity in the CQ-resistant. The ligand 
containing the amino-propyl chain (L2) exhibits the greatest antiplasmodial activity of all 
synthesized compounds. Mechanistic studies of the synthesized compounds indicate that 
they are potentially β‐hematin inhibitors, with the metal complexes being greater inhibitors 
than CQ.  
Manganese tricarbonyl complexes are known for their photochemical properties and the 
synthesized Mn(I) compounds were found to be photoactive as well. Complexes Mn-1 and 
Mn-2 release CO upon photoexcitation with UV light at 365 nm whereas the Re analogues do 
not upon long term exposure to UV. The rate of CO-release is medium-dependent and the 
Mn-1 complex releases CO faster than the Mn-2 complex. The antiplasmodial activity of 
complexes Mn-1 and Mn-2 increases 7‐ and 3‐fold respectively upon photoexcitation at 365 
nm in the K1‐CQ‐resistant strain. It was worthwhile to determine if the β‐hematin inhibition 
of the complexes improved upon photo induced CO‐release. This was indeed the case, the β‐
hematin inhibition of complex Mn-1 increased drastically upon photoexcitation. 
To the best of our knowledge, the synthesized complexes are the first Mn PhotoCORMs to be 
evaluated as antimalaria agents. These complexes exhibit good antimalarial activity and β‐
hematin inhibition with both activities increasing upon photo‐induced CO‐release. These 
results are promising and paves the way for future studies on the antimalarial evaluation of 
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5.2.  Future Outlook  
 
The results reported in this study show the potential of PhotoCORMs for the treatment of 
malaria. The study is preliminary and future work should include: 
• The identification of the photolyzed products of complexes Mn-1 and Mn-2 
• Cytotoxicity of all the synthesized and tested compounds 
• Synthesis of a fluorescent Mn-1 and Mn-2 complex 
Synthesis of the fluorescent analogues of the Mn complex is essential to determine if the 
complexes are indeed taken up by the parasite and where they localize in the cell. 
• Investigation of the concentration of Carboxy-haemoglobin (COHb) that forms in the 
presence of photo-dissociated complexes Mn-1 and Mn-2. 
The quantification of COHb that form upon treatment with complexes Mn-1 and Mn-2 upon 
photoexcitation is essential due to the known affinity of CO for haemoglobin and the toxicity 
associated with it. 
Further photophysical studies should be explored such as kinetic and quantum yield studies 
to determine the exact rate of CO-release. DFT and TDDFT calculation can be performed to 
give insight into the electronic structure of the metal complexes and determine what optical 
transitions occur when CO is released 
The antiplasmodial activity of the synthesized compounds could be improved by separating 
the compounds into two components as shown in Figure 5.1. The ligand L2 exhibited greater 
antimalarial activity than its respective Mn complex and the antimalarial activity of the 
complex improved upon CO-release. It would be worthwhile to evaluate the antiplasmodial 
activity of the components of the hybrid molecule as shown in Figure 5.1. Doing so will help 
to determine if the components exhibit a synergistic or antagonistic effect.  
 
  












Future work should involve the synthesis of a prodrug that releases CO and can be 
administered in combination with a pharmacophore. This will help determine if having the 
CO-releasing scaffold attached to the pharmacophore is more advantageous. A Possible 
example of this is shown in Figure 5.2 in which the compound could be considered a prodrug 










Figure 5.1. Combinations of components of the hybrid molecules that should be 
synthesized and evaluated for their antimalarial activity. 
Figure 5.2. Possible prodrug that could be synthesized as a transporter of CO. 
  




6.1.  Chemicals and General Methods  
 
All reagents were purchased from Merck, KIMIX and Science World and were used without 
further purification. All solvents were of analytical grade and in the case of reactions done 
under Ar, the solvents were dried over molecular sieves. All reactions were monitored by TLC 
using aluminium-backed precoated silica-gel 60 F254 plates purchased from Merck. TLC plates 
were observed under ultraviolet light at 254 nm. All synthesised compounds were dried under 
high vacuum. All deuterated solvents that were used for NMR spectroscopy were purchased 
from Sigma-Aldrich. Purification using column chromatography was carried out using silica-
gel (Fluka Silica Gel 60, 40-63 microns).  
 
6.2.   Spectroscopic and Analytical Methods  
 
Nuclear magnetic resonance (NMR) spectra were either recorded on a Bruker Topsin GmbH 
400 MHz spectrometer (1H at 400.22 MHz; 13C{1H} at 100.65 MHz) or Varian Mercury 300 (1H 
at 300.08 MHz at 13C{1H}: 75.46 MHz) which were equipped with a Bruker Biospin GmbH 
casing and sample injector at 30 °C. Chemical shifts for 1H and 13C{1H} NMR are all reported 
using tetramethylsilane (TMS) as an internal standard. Chemical shifts and J-couplings are 
reported in ppm and Hz respectively. NMR spectra were recorded using either deuterated 
dimethylsulfoxide (DMSO-d6) or deuterated chloroform (CDCl3). Infrared (IR) spectroscopy 
were recorded using a Perkin-Elmer Spectrum 100 FT-IR spectrometer and Attenuated Total 
Reflectance (ATR) or a NaCl solution cell for solution-state IR in which the vibrations were 
measured in 𝑐𝑚−1. Melting points were obtained using a Büchi Melting Point Apparatus B-
540. High-resolution Mass spectrometry was recorded on a Waters Synapt G2, ESI probe, ESI 
Pos, Cone Voltage 15 V machine using the positive mode.  
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6.3.  Synthesis of the terminal alkyne 







4-Aminophenol (972 mg, 8.91 mmol, 1 eq.) and 2-pyridinecarboxaldehyde (1.69 mL, 17.8 
mmol, 2 eq.) were dissolved in methanol (100 mL). The reaction mixture was refluxed (65℃) 
for 21 hours and was monitored via Thin Layer Chromatography using a mobile phase of 20% 
petroleum ether/ethyl acetate. The excess solvent was removed via rotary evaporation and 
the residue was dissolved in minimal hot methanol. The round bottom flask containing the 
crude product in methanol was cooled on ice to form a beige precipitate. Compound 1 was 
collected via suction filtration and washed with ice-cold methanol. 
Yield: 1.48 g, 84%. Melting point: 186.2-187.8 ℃ (lit.,2 186–187 ℃). 1H NMR (300 MHz, 
(CD3)2SO): δ= 9.61 (s, 1H, OH) 8.67 (d, 3JHH=4.80 Hz, 1H, H-1), 8.58 (s, 1H, H-6), 8.10 (d, 
3JHH=7.90 Hz, 1H, H-4), 7.90 (td, 4JHH=1.22 Hz, 3JHH=7.90 Hz,1H, H-3), 7.41-7.58 (m, 1-H, H-2), 
7.28 (d, 3JHH=8.70, 2H, H-9), 6.82 (d, 3JHH=8.70 Hz, 2H, H-8). 13C {1H} NMR (101 MHz, (CD3)2SO: 
δ 156.99 (C-10), 156.88 (C-6), 154.52 (C-7),149.46 (C-1), 141.49 (C-5), 136.78 (C-3), 124.96 (C-
2), 122.82 (C-9), 120.62(C-4), 115.77 (s, C-8). IR (ATR, 𝒄𝒎−𝟏): 2465‐2988 (broad, medium, 
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Compound 1 (526 mg, 2.65 mmol, 1 eq.), potassium carbonate (1.87 g, 13.6 mmol, eq.) and 
18-crown-6 ether (361 mg, 1.37 mmol, 0.5 eq.) were mixed in acetone (20 mL). Propargyl 
bromide (0.2 mL, 2.65 mmol, 1 eq.) was diluted with acetone (10 mL) and added dropwise to 
the stirring reaction mixture. The solution was refluxed for 72 hours (56 ℃). The reaction was 
monitored using TLC. The solvent was removed via rotary evaporation and left in the fridge 
for 2 hours while still containing K2CO3. DCM (40 mL) was added to the residue and excess 
K2CO3 was filtered by gravity. The filtrate was washed with H2O (3 × 30 mL). The combined 
organic extracts were washed with a saturated solution of ammonium chloride in H2O (2 X 30 
mL) and once more with H2O (30 mL). The combined organic extracts were dried with 
anhydrous Na2SO4 which was subsequently filtered by gravity, resulting in a brown oil which 
underwent slow evaporation to form brown crystals (2).  
Yield: 490 mg, 81%. Melting point: 104.4-106.2 ℃. 1H NMR (300 MHz, (CD3)2SO) δ= 8.69 (d, 
3JHH = 4.8 Hz, 1H, H-1), 8.69 (s, 1H-6), 8.13 (d, 3JHH = 7.9 Hz, 1H, H-4), 7.93 (ddd, 3JHH = 7.9 Hz, 
4JHH= 1.7 Hz, 0.8 Hz, 1H, H-3), 7.49 (ddd, 3JHH = 7.5 Hz, 3JHH=4.8 Hz, 4JHH=1.7 Hz, 1H, H-2), 7.41 
– 7.36 (m, 2H, H-9), 7.08 – 7.03 (m, 2H, H-8), 4.83 (d, 4JHH = 2.4 Hz, 2H, H-11), 3.56 (t, 4JHH = 2.4 
Hz, 1H, H-13). 13C {1H} NMR (101 MHz, (CD3)2SO: δ 158.64 (C-6), 156.39 (C-10), 154.37 (C-7), 
149.52 (C-1), 143.98 (C-5), 132.89 (C-3), 125.23 (C-2), 122.57 (C-9), 121.03 (C-8), 79.27 (C-12), 
78.17 (C-13), 55.77 (C-11). IR (ATR, 𝒄𝒎−𝟏): 3171 (sharp, medium, ≡C-H), 2964 (Sharp, weak, 
C≡C), 1623 (sharp,weak,C=Nimine), 1600 (sharp, weak, C=Npyridyl), 1579 (sharp, strong, C=C), 
1239 (sharp, strong, C-O-C). 
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4,7-Dichloroquinoline (561 mg, 2.83 mmol, 1 eq.) was dissolved in anhydrous DMF (5 mL). 
NaN3 (361 mg, 5.55 mmol, 2 eq.) was added and the resulting mixture was stirred at 65 ℃  for 
6 hours while being monitored via TLC in a 30% ethyl acetate/hexane. After completion, the 
mixture was cooled to room temperature. Ethyl acetate (20 mL) was added to the reaction 
mixture and excess NaN3 was filtered by gravity. The filtrate was washed with H2O (3 × 30 
mL), brine (2 × 30 mL) and then H2O (2 × 30 mL). The combined organic extracts were dried 
over anhydrous Na2SO4. The Na2SO4 was removed via gravity filtration and the solvent 
removed from the filtrate via rotary evaporation. The crude product was recrystallised from 
hot DCM/ cold hexane to yield compound 3 as yellow needle crystals.  
Yield: 359 mg, 62%. Melting point: 116.3-118.5 ℃ (lit.,3 115 ℃). 1H NMR (300 MHz, CDCl3): 
δ= 8.83 (d, 3JHH=4.94 Hz, 1H, H-1), 8.07 (d, 5JHH=2.07 Hz, 1H, H-8), 8 (d, 3JHH= 8.94 Hz, 1H, H-6), 
7.49 (dd, 5JHH= 2.07 Hz, 3JHH=8.94 Hz, 1H, H-5), 7.13 (d, 3JHH=4.94 Hz, 1H, H-2). 13C {1H} NMR 
(101 MHz, (CDCl3) : δ 151.37 (C-1), 149.65 (C-9), 146.77 (C-7), 136.97 (C-3), 128.23 (C-8), 
127.81 (C-5), 123.93 (C-6), 120.03 (C-4), 108.66 (C-2).  IR (ATR, 𝒄𝒎−𝟏): 2117 (sharp, strong, 
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6.5. Synthesis of (7-chloroquinolin-4-yl)-amino]propane   
derivatives.  









4,7-Dichloroquinoline (1.44 g, 7.25 mmol, 1 eq.) and 3-aminopropan-1-ol (5.5 mL, 72.5 mmol, 
10 eq.) were heated to 80 ℃ for 1 hour without stirring. The temperature was then increased 
to 130 ℃ and the solution was stirred under reflux conditions for 16 hours. The reaction was 
allowed to cool to room temperature. H2O (10 mL) was added, resulting in the immediate 
formation of a white precipitate. The desired product (4) was collected via suction filtration 
and washed with H2O, yielding a white solid that was dried in vacuum.  
 
Yield: 904 mg, 62%. Melting point: 142.2-143.4 ℃ (lit.,4 142-143). 1H NMR (300 MHz, DMSO) 
δ 8.39 (d, 3JHH = 5.4 Hz, 1H, H-7), 8.24 (d, 3JHH = 9.0 Hz, 1H, H-11), 7.77 (d, 5JHH = 1.6 Hz, 1H, H-
9), 7.43 (dd, 3JHH = 9.0, 3JHH= 1.6 Hz, 1H, H-12), 7.27 (brs, 1H, H-4), 6.47 (d, 3JHH = 5.4 Hz, 1H, H-
6), 4.56 (brs, 1H, OH), 3.55 (t, 3JHH = 5.9 Hz, 2H, H-1), 3.33 (q, 3JHH= 6.4 Hz, 2H, H-3), 1.82 (p, 
2H, H-2). 13C {1H} NMR (101 MHz, (CD3)2SO) δ 151.91 (C-5), 150.49 (s,C-11), 148.99 (C-8), 
133.45 (C-12), 127.63 (C-7), 124.09 (C-9), 124.13 (C-10), 117.74 (C-3), 98.56 (C-6), 48.46 (C-1), 
40.94 (C-3), 31.23 (C-2). IR (ATR, 𝒄𝒎−𝟏): 3312 (broad, weak, OH), 3058 (sharp, weak, NH), 
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Compound 4 (513 mg, 2.55 mmol, 1 eq.) was dissolved in excess thionyl chloride (3.70 mL, 
51.1 mmol, 20 eq.). Catalytic amounts of DMF (50 μL) was added and the reaction was set to 
stir under argon at ambient temperature for 16 hours. The excess thionyl chloride was 
quenched using a saturated solution of sodium bicarbonate in H2O. Compound 5a was 
collected via suction filtration and washed with ice-cold ethyl acetate. The beige solid was 
dried in vacuum.  
 
Yield: 447 mg, 67 %. Melting point: 127.9-128.2 ℃.  1H NMR (300 MHz, DMSO) δ 9.50 (br s, 
1H, H-4), 8.71 (d, 3JHH= 7 Hz, 1H, H-7), 8.52 (d, 3JHH= 9.1 Hz, 1H, H-11), 8.09 (d, 5JHH = 2.1 Hz, 
1H, H-9), 7.75 (dd, 3JHH = 9.1, 3JHH= 2.1 Hz, 1H, H-12), 6.85 (d, 3JHH = 7 Hz, 1H, H-6), 3.80 (t, 3JHH= 
6.4 Hz, 2H, H-1), 3.63 (q3JHH= 6.4 Hz, 2H, H-3), 2.16 (p, 3JHH = 6.4 Hz, 2H, H-2). ). 13C {1H} NMR 
(101 MHz, (CD3)2SO) δ 155. 11 (C-5), 143.12 (C-11), 139.39 (C-8), 126.63 ( C-12), 126.11 (C-7), 
122.92 (C-9), 119.54 (C-10), 115.83 (C-3) 98.95 (C-6), 44.19 (C-1), 39.88     (C-3), 30.96 (C-2).  
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Methansulfonyl chloride (501 mg, 2.49 mmol, 1 equiv) was added to a solution of compound 
4 (288 μL, 3.73 mmol, 1.5 equiv) and Et3N in THF (10 mL) at 0 ℃. The mixture was stirred for 
3 hours after which a saturated solution of NaHCO3 (20 mL) was added. Compound 5b was 
extracted with chloroform (3 × 20 mL). The combined organic extracts were dried over 
anhydrous Na2SO4, which was subsequently filtered via gravity filtration. The solvent was 
removed from the filtrate using rotary evaporation to yield crude compound 11 as an off-
white powder. The crude product was purified via column chromatography using MeOH: DCM 
in increasing ratios up to 10:9.   
Yield: 447 mg, 67 %. 1H NMR (300 MHz, DMSO) δ 8.40 (d, 3JHH = 5.3 Hz, 1H, H-7), 8.25 (d, 3JHH 
= 9.0 Hz, 1H, H-11), 7.78 (d, 5JHH = 2.2 Hz, 1H, H-9), 7.45 (dd, 3JHH = 9.0 Hz, 5JHH= 2.2 Hz, 1H, H-
12), 7.31 (t, 4JHH = 5.3 Hz, 1H, H-4), 6.50 (d, 3JHH = 5.3 Hz, 1H, H-6), 4.33 (t, 3JHH = 6.4 Hz, 2H, H-
1), 3.37 (q, 3JHH= 6.4 Hz, 2H, H-3), 3.19 (s, 3H, CH3), 2.07 (q, J = 13.1, 3JHH= 6.4 Hz, 3H, H-2). 13C 
{1H} NMR (101 MHz, (CD3)2SO) δ 155.48 (C-5), 150.32 (C-11), 148.34 (C-8), 133.35      (C-12), 
126.95 (C-7), 124.01 (C-9), 124.10 (C-10), 117.34(C-3) 98.80 (C-6), 58.30 (C-1), 39.21 (C-3), 









136 Chapter 6              Experimental 
6.5.4. Synthesis of 3-[(7-chloroquinolin-4-yl)amino]azidopropane (6). 









Compound 5a (292 mg, 1.14 mmol, 1 eq.) was dissolved in DMF (4 mL). NaN3 (128 mg, 1.97 
mmol, 2 eq.) was added and the reaction was heated to 80 ℃ under reflux and argon for 16 
hours. Ethyl acetate (30 mL) was added and the organic layer washed with H2O (1 × 30 ml), 
brine (2 × 30 mL) and H2O (2 × 30 mL). The organic extracts were collected and dried over 
anhydrous MgSO4. The MgSO4 was removed via gravity filtration and the solvent was 
removed from the filtrate via rotary evaporation resulting in a pale-yellow product (6) that 
was dried in vacuum.  
 
Yield: 80.8 mg, 23 %. Melting point: 149-150.7 ℃ (lit.,4 149-150 ℃). 1H NMR (300 MHz, 
DMSO) δ 8.41 (d, 3JHH = 5.4 Hz, 1H, H-7), 8.27 (d, 3JHH = 9.0 Hz, 1H, H-11), 7.79 (d, 5JHH = 2.2 Hz, 
1H, H-9), 7.46 (dd, 3JHH = 9.0 Hz, 3JHH= 2.2 Hz, 1H, H-12), 7.30 (t, 4JHH = 5.4 Hz, 1H, H-4), 6.50 (d, 
3JHH = 5.4 Hz, 1H, H-6), 3.50 (t, 3JHH = 6.7 Hz, 2H, H-1), 3.63 (q, 3JHH =6.7 Hz, 2H, H-3), 1.93 (q, 
3JHH = 6.7 Hz, 2H, H-2). 13C {1H} NMR (101 MHz, (CD3)2SO):  δ 151.86 (C-5), 149.83 (C-11), 
149.02 (C-8), 133.31 (C-12), 127.49 (C-7), 124.01 (C-9), 122.11 (C-10), 117.44 (C-3) 98.62 (C-
6), 48.53 (C-1), 40.10 (C-3), 27.09 (C-2).  IR (ATR, 𝒄𝒎−𝟏) 2111 (sharp, strong, N3), 3191 (sharp, 
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To a solution of compound 11 (450 mg, 0.151 mmol, 1 eq.) in anhydrous DMF, NaN3 (196 mg, 
0,301 mmol, 2 eq.) was added and the mixture heated at 55 ℃ for 20 hours. H2O (30 mL) was 
added and the product was extracted with toluene (3 X 50 mL). The organic extracts were 
washed with a saturated brine solution (2X 50 mL) and then with H2O (2 X 50 mL). The organic 
extracts were then dried over Na2SO4, which was subsequently filtered using gravity filtration. 
The solvent was removed from the filtrate via rotary evaporation. The crude product was 
purified via column chromatography using increasing rations of MeOH: DCM (9:1) to yield the 
product (6) as a pale-yellow solid. 
Yield: 207 mg, 52%. 1H NMR (300 MHz, DMSO) δ 8.41 (d, 3JHH = 5.4 Hz, 1H, H-7), 8.27 (d, 3JHH 
= 9.0 Hz, 1H, H-11), 7.79 (d, 5JHH = 2.2 Hz, 1H, H-9), 7.46 (dd, 3JHH = 9.0, 5JHH= 2.2 Hz, 1H, H-12), 
7.30 (t, 4JHH = 5.4 Hz, 1H, H-4), 6.50 (d, 3JHH = 5.4 Hz, 1H, H-6), 3.50 (t, J = 6.7 Hz, 2H, H-1), 3.38 
– 3.33 (m, 2H, H-3), 1.93 (q, J = 6.8 Hz, 2H, H-2). 
 
6.6.  The general method for the synthesis of 7-
chloroquinoline-1,2,3-triazole ligands 
 
A Schlenk tube covered in aluminium foil was evacuated and filled with argon after which CuI 
(10 mol %) and DIPEA (1 mL) were added and allowed to stir for 10 minutes. Compound 2 (1 
eq.) in dry DCM (1 mL) was added to the stirring solution of CuI and allowed to stir for a further 
5 minutes. Compound 3 (1 eq.) in DCM (1 mL) was added and the reaction mixture was 
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refluxed under argon for 4 or 18 hours. The completion of the reaction was determined by 
TLC in ethyl acetate: petroleum either mixture in ration 8:2. DCM (50 mL) was added and the 
precipitate was filtered via gravity filtration. The filtrate was washed with a saturated solution 
of NH4Cl (2 X 50 mL) and H2O (2 X 50 mL). The combined organic extracts were dried over 
anhydrous Na2SO4 which was subsequently filtered by gravity. The solvent was removed from 
the filtrate via rotary evaporation. The crude product was recrystallized from either acetone 
or diethyl ether and collected using suction filtration to produce the ligands as beige powders 
which were dried in vacuo.  
 









CuI (12.0 mg, 0.063 mmol, 10 mol %), DIPEA (1 mL), compound 2 (255 mg, 1.08 mmol,0.83 
mmol,1.3 eq.) and compound 3 (170 mg, 1 eq.) were reacted in DCM for 4 hours. Ligand L1 
was purified via a water wash and recrystallization from acetone. The product (L1) was 
isolated as a beige powder. 
Yield: 200 mg, 56%. Melting point: 207.5-209.2 ℃ (decomp). 1H NMR (300 MHz, (CD3)2SO) 
δ= 9.23 (d, 3JHH = 4.7 Hz, 1H,H-16), 9.05 (s, 1H, H-13), 8.77 (d, 3JHH = 4.8 Hz, 1H, H-1), 8.70 (s, 
1H, H-6), 8.36 (d, 5JHH = 2.1 Hz, 1H, H-18), 8.21 (d, 3JHH = 7.9 Hz, 1H, H-3), 8.07 (d, 3JHH = 9.1 Hz, 
1H, H-20), 8.00 (td, 3JHH = 7.9 Hz, 4JHH= 1.4 Hz, 1H, H-4), 7.95 (d, 3JHH = 4.7 Hz, 1H, H-15), 7.86 
(dd, 3JHH = 9.1 Hz, 5JHH 2.1 Hz, 1H, H-21), 7.57 (ddd, 3JHH = 7.9 Hz, 3JHH= 4.8 Hz, 4JHH= 1.4 Hz, 1H, 
H-2), 7.49 (d, 2H, 3JHH=9.0 Hz H-9 ), 7.26 (d, 3JHH = 9.0 Hz, 2H, H-8), 5.38 (s, 2H, H-11). 13C {1H} 
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NMR (101 MHz, (CDCl3): δ  IR (ATR, 𝑐𝑚−1): 168.66 (C-10), 168.04 (C-6), 158.43 (C-5), 154.85 
(C-1), 152.71 (C-16), 150.57 (C-17), 143.11(C-7) , 141.84(C-4) , 140.11 (C-19), 133.74 (C-14) , 
124.48 (C-21), 124.23 (C-2), 123.96 (C-3), 123.42 (C-21), 122.07 (C-13), 115.42 (C-20), 114.95 
(C-9), 114.57 (C-22), 98.52 (C-8), 61.10 (C-11). IR (ATR, 𝒄𝒎−𝟏) 1623 (sharp, weak, imine- C=N), 
1595 (sharp, medium, C=C), 1579 (sharp, strong, pyridyl-C=N) 1562 (sharp, strong, quinoline-
C=N). 
 







CuI (11.0 mg, 10 mol %), DIPEA (1 mL), compound 2 (137 mg, 0.582 mg ,1.3 eq.) and compound 
6 (117 mg, 0.447 mmol, 1 eq.) were reacted in DCM for 18 hours. Ligand L2 was purified via a 
water wash and recrystallization from diethyl ether. The product (L2) was isolated as a beige 
powder. The crude product was crystallised via slow crystallisation in diethyl ether to yield 
compound 13 as a beige powder.  
Yield: 92.9 mg, 42%. Melting point: 153.2-154.8 ℃.  1H NMR (300 MHz, DMSO) δ 8.71 (d, 3JHH 
= 4.4 Hz, 1H, H-1), 8.62 (s, 1H, H-6), 8.40 (d, 3JHH = 5.4 Hz, 1H, H-20), 8.30 (s, 1H, H-13), 8.27 
(d, 3JHH = 9.1 Hz, 1H, H-24), 8.14 (d, 3JHH = 7.8 Hz, 1H, H-4), 7.95 (t, 3JHH = 7.8 Hz, 1H, H-3), 7.79 
(d, 3JHH = 2.3 Hz, 1H, H-22), 7.54 – 7.50 (dd, 3JHH = 7.8 Hz, 3JHH= 4.4 Hz, 1H, H-2), 7.47 (dd, 3JHHH 
= 9.1 Hz, 5JHH= 2.3 Hz, 1H, H-25), 7.39 (d, 3JHH = 8.9 Hz, 2H, H-9), 7.34 (brs,1H, H-17),7.12 (d, 
3JHH = 8.9 Hz, 2H, H-8), 6.44 (d, 3JHH = 5.4 Hz, 1H, H-19), 5.19 (s, 2H, H-11), 4.55 (t, 3JHH = 6.9 Hz, 
2H, H-14), 3.39 (d, 3JHH = 6.9 Hz, 2H, H-16), 2.25 (q, 2H, H-15). 13C {1H} NMR (101 MHz, 
(CD3)2SO: δ 158.85 (C-6), 157.76 (C-10), 154.75 (C-18), 152.32 (C-20), 150.01 (C-1), 149.41      
(C-5), 143.64 (C-7), 143.063 (C-12), 137.36 (C-3),133.84 (C-23) 127.88 (C-22), 125.71 (C-2), 
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125.077 (C-13), 124.62 (C-25), 124.54 (C-24), 123.17 (C-9), 121.32 (C-4), 117.89 (C-26), 115.44 
(C-8), 99.05 (C-19), 61.76 (C-11), 47.48 (C-14), 39.98 (C-16), 28.84 (C-15). IR (ATR, 𝒄𝒎−𝟏): 
1612 (sharp, weak, C=Nimine,quinoline), 1592 (sharp, strong, C=Npyridine). 
 
6.7. The general method for the synthesis of metal tricarbonyl 
complexes 
 
Either [MnBr(CO)5] or [ReCl(CO)5] in DCM (10 mL) was added dropwise to a stirring solution 
of either ligand L1 or L2) in DCM (20 mL). The reaction mixture was allowed to stir at room 
temperature or under reflux conditions while being wrapped in aluminium foil for protection 
against light. The solvent was removed via rotary evaporation and the product recrystallized 
from DCM/pentane in the dark. The desired complex was collected via suction filtration and 
dried in vacuo. 









[MnBr(CO)5] (51.6 mg, 0.188 mmol, 1.3 eq.) and ligand L1 (64.0 mg, 0.145 mmol, 1 eq.) were 
reacted in DCM at room temperature for 72 hours. The solvent was removed via rotary 
evaporation and the residue was dissolved in ethyl acetate.  The impurities were filtered off 
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using gravity filtraction and the solvent was removed from the filtrate via rotary evaporation. 
The product Mn-1 was recrystallized from DCM/pentane to produce an orange powder  
Yield: 104 mg, 93%. Melting point: 145.2-147.8 ℃ (decomp).   1H NMR (300 MHz, DMSO): δ 
9.22 (d, 3JHH = 5.2 Hz, 1H, H-1), 9.17 (d, 3JHH = 4.6 Hz, 1H, H-16), 9.02 (s, 1H,H-13), 8.87 (s, 1H, 
H-6), 8.30 (d, 5JHH = 2.0 Hz, 1H, H-18), 8.25 (d, J = 4.2 Hz, 2H, H-3, H-4), 8.02 (d, J = 9.1 Hz, 1H, 
H-20), 7.89 (d, J = 4.6 Hz, 1H, H-15), 7.82 (d, 5JHH = 2.0 Hz, 1H, H-21), 7.80 – 7.77 (m, 1H, H-2), 
7.60 (d, 3JHH = 8.8 Hz, 2H, 9), 7.32 (d, 3JHH = 8.8 Hz, 2H, H-8), 5.42 (s, 2H, H-11). 13C {1H} NMR 
(101 MHz, (CD3)2SO: δ 222.22 (C≡O), 221.18 (C≡O), 218.83 (C≡O), 167.18 (C-6), 157.90         
(C-10), 154.96 (C-5), 153.59 (C-1), 152.36 (C-16), 149.31 (C-17), 145.53 (C-12), 143.27 (C-7), 
140.43 (C-3), 139.16 (C-19), 135.35 (C-14), 129.14 (C-20), 128.78 (C-4), 128.06 (C-21), 126.99 
(C-13), 125.29 (C-18), 123.15 (C-9), 120.19 (C-22), 117.09 (C-15), 115.14 (C-8), 61.53 (C-11). IR 
(ATR, 𝒄𝒎−𝟏): 2024 (sharp, strong C≡O), 1914 (broad, strong, C≡O), 1610 (sharp, weak, 
C=Nimine,quinoline), 1598 (sharp, strong, pyridyl-C=N), 1564 (sharp, medium, C=C). MS (HR-ESI, 
m/z): 660.9620 (100% [M+H+]), 660.7680 (calc.). 
 









[ReCl(CO)5] (59.1 mg, 0.163 mmol, 1 equiv) and ligand L1 (70.5 mg, 0.156 mmol, 1 equiv) were 
reacted in DCM (20 mL) at 40 ℃ for 4 days. The product was recrystallized from DCM/pentane 
to produce Re-1 as a yellow powder.  
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Yield: 99.7 mg, 84%.  Melting point: 197.7-199.5 ℃ (decomp). 1H NMR (300 MHz, DMSO) δ 
9.31 (s, 1H, H-6), 9.18 (d, 3JHH = 4.7 Hz, 1H, H-16), 9.07 (d, 3JHH = 6.2 Hz, 1H, H-1), 9.03 (s, 1H, 
H-13), 8.37 (td, 4JHH=1.2 Hz, 3JHH=5.4 Hz, 1H, H-4), 8.35 (d, 3JHH=5.4 Hz 1H, H-3), 8.31 (d, 5JHH = 
2.1 Hz, 1H, H-18), 8.03 (d, 3JHH = 9.0 Hz, 1H, H-20), 7.90 (d, 3JHH = 4.7 Hz, 1H, H-15), 7.84 (ddd, 
3JHH = 6.2 Hz, 3JHH = 5.4 Hz, 4JHH = 1.2 Hz, 1H, H-2) 7.81 (dd, 5JHH=2.1 Hz, 3JHH=9.0 Hz, 1H H-21), 
7.62 (d, 3JHH = 8.9 Hz, 2H, H-9), 7.34 (d, 3JHH = 8.9 Hz, 2H, H-8), 5.44 (s, 2H, H-11). 13C {1H} NMR 
(101 MHz, (CD3)2SO) δ 197.73 (C≡O), 197.19 (C≡O), 187.81 (C≡O), 168.63 (C-6), 158.73 (C-
10), 155.43 (C-5), 153.30 (C-16), 152.90 (C-1), 149.45 (C-17), 144.17 (C-12), 143.36 (C-7), 
140.23 (C-4),140.48 (C-19) 135.53 (C-19), 130.24 (C-3), 129.71 (C-2), 129.17 (C-21), 128.28        
(C-18), 127.22 (C-13), 125.90 (C-20), 123.93 (C-9), 120. 45 (C-14), 117.31 (C-15), 115.54 (C-8), 
61.32 (C-11). IR (ATR, 𝒄𝒎−𝟏): 2019 (sharp, strong, C≡O), 1886 (broad, strong, C≡O), 1614 
(broad, weak, C=Nimine, quinoline), 1595 (broad, weak, C=Npyridine). MS (HR-ESI, m/z): 747.0309 
(100% [M+H+]),747.5880 (calc.). 
 








[MnBr(CO)5] (48.8 mg, 0.177 mmol, 1.3 equiv) and L1 (67.1 mg,0.135 mmol, 1 equiv) were 
reacted at 25℃ in DCM for 24 hours. The product (Mn-2) was recrystallized from 
DCM/pentane to yield an orange powder.  
Yield: 67.5 mg, 70%. Melting point: 108.4-110 ℃.  1H NMR (300 MHz, DMSO) δ 9.23 (d, 3JHH 
= 5.2 Hz, 1H, H-1), 8.86 (s, 1H, H-6), 8.41 (d, 3JHH = 5.5 Hz, 1H, H-20), 8.34 (s, 1H, H-13), 8.29 – 
8.24 (m, 1H,H-3, H-4, H-24), 8.26, 7.83 – 7.77 (m, 2H, H-2,22), 7.58 (d, 3JHH = 8.9 Hz, 2H, H-9), 
7.47 (dd, 3JHH = 8.9 Hz, 5JHH= 1.9 Hz, 1H, H-25), 7.34 (brs, 1H, H-17), 7.24 (d, 3JHH = 8.9 Hz, 2H, 
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H-8), 6.46 (d, 3JHH = 5.5 Hz, 1H, H-19), 5.24 (s, 2H, H-11), 4.56 (t, 3JHH = 6.9 Hz, 2H, H-14), 3.33 
(d, 3JHH = 6.9 Hz, 2H, H-16), 2.26 (q, 2H, H-15). 13C {1H} NMR (101 MHz, (CD3)2SO: δ 222.33 
(C≡O), 221.22 (C≡O), 219.25 (C≡O), 167.85 (C-6), 158.42 (C-10), 154.99 (C-18), 153.69 (C-1) 
151.78 (C-20), 149.92 (C-5), 149.00 (C-7), 145.25 (C-12), 139.17 (C-3),133.37 (C-23) 129.13 (C-
22), 128.03 (C-2), 124.718 (C-13), 124.05 (C-25, 24), 123.05 (C-9), 122.43 (C-4), 117.76 (C-26), 
115.04 (C-8), 98.700 (C-19), 61.4 (C-11), 47.41 (C-14), 40.00 (C-16), 28.39 (C-15).  IR (ATR, 
𝒄𝒎−𝟏): 2024 (sharp, strong, C≡O), 1914 (C≡O), 1603 (sharp, strong, C=Nimine, quinoline), 1592 
(sharp, weak, C=Npyridine). MS (HR-ESI, m/z): 736.4257 (100% [M+MeCN+Na]+), 736.4400 
(calc). 
 








[ReCl(CO)5] (43.0 mg, 0.012 mmol, 1 eq.) and L2 (60.6 mg, 0.012 mmol, 1 equiv) were reacted 
in DCM at 30 ℃ for 24 hours. A crude product of Re-2 was obtained via recrystallization in 
DCM and pentane to yield a bright yellow powder. 
Yield: 71.3 mg, 73%. 1H NMR (300 MHz, DMSO): δ 9.29 (s, 1H, H-6), 9.06 (d, 3JHH = 5.4 Hz, 1H, 
H-1), 8.41 (d, 3JHH = 5.5 Hz, 2H, H-20), 8.36 (dd, 3JHH = 7.0 Hz, 2H, H-24), 8.33 (s, 1H, H-13), 8.30 
(d, 4JHH = 1.4 Hz, 1H, H-4), 8.26 (br s, 1H, H-3), 7.87 – 7.81 (m, 1H, H-2), 7.80 (d, 5JHH = 2.1 Hz, 
1H, H-25), 7.58 (d, 3JHH = 9.0 Hz, 2H, H-9), 7.50 – 7.45 (m, 2H, H-25), 7.39 (d, 3JHH = 8.8 Hz, 2H, 
H-17), 7.25 (d, 3JHH = 9.0 Hz, 2H, H-8), 6.47 (d, 3JHH = 5.5 Hz, 1H, H-19), 5.25 (s, 2H, H-11), 4.55 
(t, 3JHH = 6.9 Hz, 4H, H-14), 3.39 (dd, J = 14.0 Hz, 3JHH= 6.9 Hz, 3H, H-16), 2.34 – 2.20 (m, 4H, H-
15). ).  IR (ATR, 𝒄𝒎−𝟏): 2019 (sharp, strong, C≡O), 1889 (C≡O), 1603 (sharp, weak, C=Nimine, 
quinoline), 1592 (sharp, weak, C=Npyridine) 
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6.8. Reactivity studies: [2+1] approach 













A Schlenk flask was evacuated and purged with argon, after which complex Mn-1 (40.9 mg, 
0.062 mmol, 1 eq.) and MeCN (30 mL) was added. Silver trifluoromethanesulfonate (31.2 mg, 
0.124 mmol, 2 eq.) in acetonitrile (5 mL) was added to the stirring solution. The mixture was 
stirred under argon conditions for 2.5 hours. Isoniazid or 4-picoline (12 μL, 0.124 mmol, 2 eq.) 
in MeCN (5 mL) was added and the reaction mixture stirred for 20 hours. The solvent was 
removed via rotary evaporation. DCM (~20 mL) was added and the resulting precipitate 
filtered through celite. The solvent was reduced from the filtrate and the product was 
attempted to be purified via recrystallisation in DCM/hexane afforded a bright yellow 
powder.  
1H NMR (300 MHz, DMSO) δ 9.31 (d, J = 5.3 Hz, 1H, H-1), 9.19 (d, J = 4.7 Hz, 1H, H-16), 9.04 (s, 
1H, H-13), 9.00 (s, 1H, H-6), 8.39 (d, J = 7.7 Hz, 2H, H-a), 8.35 (br s, 1H, H-21), 8.33 (d, J = 2.0 
Hz, 2H, H-4,3), 8.30 (d, J = 7.4 Hz, 1H, H-18), 8.03 (d, J = 9.1 Hz, 2H, H-18), 7.94 (br s, 1H, H-2), 
7.90 (d, J = 4.7 Hz, 2H, 15), 7.82 (dd, J = 9.1, 2.2 Hz, 2H, H-20), 7.60 (t, J = 8.6 Hz, 3H, H-9), 7.38 
(d, J = 8.9 Hz, 2H, H-9), 7.35 (d, J=7.7 Hz, 2H, H-b) 5.45 (s, 2H, H-11), 2.08 (s, 3H, CH3). 
 
  
145 Chapter 6              Experimental 







To a solution of 4-(pyridinylimine)phenol (1) (105 mg, 0.530 mmol, 1 eq.) in MeOH (20 mL), 
[MnBr(CO)5] (173 mg, 0.635 mmol, 1.2 eq.) in MeOH (10 mL) was added to a flask covered in 
aluminium foil. The reaction mixture was heated to 40℃ and allowed to stir under reflux 
conditions for 18 hours. The solvent was removed via rotary evaporation and the residue 
recrystallized by layering pentane over DCM. Complex Mn-4 was isolated as a dark orange 
powder. 
Yield: 96 mg, 43%. 1H NMR (300 MHz, DMSO) δ 9.88 (s, 1H, OH ), 9.88 (brs, 1H,H-1), 8.79 (s, 
1H, H-6), 8.22 (brs, 2H, H-4,3), 7.76 (brs, 1H, H-2), 7.44 (d, 3JHH = 7.3 Hz, 2H, H-9), 6.91 (d, 3JHH 
= 7.3 Hz, 2H, H-9). IR (ATR, 𝒄𝒎−𝟏): 2027 cm-1 (sharp, strong, C=O), 1918 cm-1 (sharp, strong, 
C=O), 1604 (sharp, weak, C=Nimine), 1591 (sharp weak, C=Npyridine).   
 








To a stirring solution of complex Mn-4 (78.5 mg, 0.188 mmol, 1 eq.) in DCM (20 mL), AgPF6 
(56.9 mg, 0.225 mmol, 1.2 eq.) was added. The reaction mixture was stirred at room 
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temperature under an inert atmosphere for 18 hours in the dark. 4-picoline (21.9 μL, 2.25 
mmol, 1.2 eq.) was added to the solution was stirred at room temperature for 48 hours. The 
mixture was filtered through Celite to remove AgBr and the solvent was removed from the 
filtrate via rotary evaporation. The resulting residue was recrystallised from DCM/pentane to 
yield a yellow solid.  
Yield: 36 mg, 45%. 1H NMR (300 MHz, DMSO) δ 10.18 (s, 1H, brs, OH), 9.29 (d, 3JHH = 5.0 Hz, 
1H, H-1), 8.89 (s, 1H, H-6), 8.42 (d, 1H, 3JHH = 6.6 H-4), 8.33 (dd, 3JHH = 7.4 Hz, 3JHH= 6.6 Hz, 1H, 
H-3), 8.18 (d, 3JHH = 7.4 Hz, 1H, H-2), 7.99 (d, 3JHH = 6.4 Hz, 2H, H-a), 7.41 (d, 3JHH = 8.8 Hz, 2H, 
H-9), 7.33 (d, 3JHH = 6.4 Hz, 2H, H-b), 6.99 (d, 3JHH = 8.8 Hz, 2H, H-8), 2.30 (s, 1H, CH3). IR (ATR, 
𝒄𝒎−𝟏): 2031 cm-1, 1932 cm-1 and 1902 cm-1 (sharp, strong, C≡O), 1928 cm-1 (sharp, broad, 
C≡O).  
 
6.9.  Photochemical Studies  
6.9.1. CO-release using spectroscopic techniques 
 
Photochemical studies were recorded using IR and UV/vis spectroscopy. Infrared (IR) 
spectroscopy were recorded in DCM on a Perkin-Elmer Spectrum 100 FT-IR spectrometer and 
a NaCl plate. An initial solution state IR spectrum was recorded after which the sample was 
irradiated at 365 nm for 30 minutes using a 32 W UV lamp. Irradiation was repeated until a 
CO absorption band was no-longer observed. Electronic absorption spectra were recorded in 
a mixture of DMSO and either 0.01 M PBS (pH 7.4) or growth medium solution (5:95 % v/v). 
Electronic absorption spectra were recorded using a Cary 60 UV/Vis spectrometer with a fibre 
optic dip probe attachment. Growth medium contains RPMI with glutamine and NaHCO
3
, 
glucose, Hepes buffer, Hypoxanthine, albumax and gentamycin. Dark stability was determined 
in DMSO/PBS and DMSO/growth medium solutions were determined by taking a reading 
every 1 hour for 5 hours and a final reading was taken after 24 hours.  The solutions of 
complexes were then irradiated at 365 nm in 1-minute increments for 10 minutes, 2-minute 
increments for 2-minutes and 5-minute increments for 40 minutes. The electronic absorption 
spectrum was recorded after each irradiation period.  
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6.9.2. CO-release using the Myoglobin assay 
 
The myoglobin solution was prepared by dissolving ca. 30 mg of equine skeletal muscle 
myoglobin (purchased from Sigma Aldrich) in 10.0 mL of PBS solution (0.01 M). The 
concentration of each myoglobin solution was determined by reducing myoglobin to deoxy-
myoglobin (using sodium dithionite in PBS (0.01 M)) and using the Beer-Lambert law with the 
known extinction coefficient of deoxy-myoglobin (13.8 mM-1cm-1 at 557 nm). A stock solution 
of the complex in DMSO was prepared.  The myoglobin in PBS solution (890 μL) was degassed 
with argon and reduced with a solution of sodium dithionite (100 μL, 0.01 M). To this mixture, 
the stock complex solution (10 μL) was added to give a final volume of 1000 μL, which was 
added to a quartz cuvette. The concentrations of the stock solutions were prepared to give a 
final mixture with 10 μM metal complex, 60 μM deoxy-myoglobin and 10 mM of sodium 
dithionite. A t = 0 spectrum was recorded, after which the cuvette was irradiated at 365 nm 
with a 32 W UV lamp. The cuvette was irradiated in 1-minute increments for 10 minutes, 2-
minute increments for 10 minutes and 5-minute increments for 40 minutes. An electronic 
absorption was recorded after each irradiation period.  
 
6.10.  Antiplasmodial Studies  
 
The samples were evaluated in triplicate against both the NF54-CQ-sensitive and the K1-CQ-
resistant) strains of Plasmodium falciparum. A modified literature method was adapted for 
the in vitro cultures of asexual erythrocyte stages of the parasite.6 The in vitro antiplasmodial 
activity of the compounds was evaluated using the well-known parasitic lactate 
dehydrogenase (pLDH) assay. The method used in the assay was adapted from Makler et al.7 
The compounds were sonicated in DMSO to make stock solutions of 20 mg/mL and were 
stored at -20 °C until the day of the experiment. Relevant dilutions were made on the day of 
the assay. Chloroquine diphosphate was used as the reference drug for all experiments. A 
starting concentration of 10 000 ng/mL was used after which the solutions were serially 
diluted 2-fold in growth medium to give 10 different concentrations (the lowest being 20 
ng/ml). The 𝐼𝐶50 values of all the compounds were obtained from a non-linear dose-response 
curve which was generated using GraphPad Prism v.5.0 software.8 Antiplasmodial activity 
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with CO-release was determined by irradiating the 96-well plate for 30 minutes with a 32 W 
UV lamp before incubation with the potential drug. 
 
6.11. NP-40 Detergent-Mediated β-hematin inhibition assay 
 
The β-hematin inhibition assay was followed according to the method outlined by Carter et 
al.9 A 305.5 μM stock solution of NP-40 detergent was prepared. The respective samples were 
dissolved in the relevant volumes of DMSO to give a stock solution of 20 mM. Each sample 
(20 μL), mili-q water (140 μL) and NP-40 detergent (40 μL, 305.5 μM) was added to column 
12 of a 96 well plate. A solution of water NP-40 (305.5 μM)/DMSO (100μL) in a v/v ratio of 
7/2/1 was added to wells 1-11. A serial dilution from column 12-2 was performed, discarding 
a 100 μL from column 1. Thus column 1 serves as a blank without any sample present. A pre-
read of the plate was taken at 405 nm on a plate reader. A 25 mM stock solution of hematin 
was prepared by sonicating 16.3 mg of hematin in 1 mL of DMSO. 178 μL of this stock solution 
was then added to 20 mL of acetate buffer (1 M, pH 4.8). The hematin suspension (100 μL) 
was added to each well. The plates were covered with the plate cover and foil in the case of 
plates kept in the dark. For the CO-release study, the plate was irradiated with a 32 W UV 
lamp for 30 minutes. The plates were incubated at 37 ℃ for 16 hours in a water bath. The 
analysis was carried out using the pyridine-ferrichrome method developed by Ncokazi and 
Egan.10 A solution of pyridine/H2O/acetone/ HEPES buffer (2 M, pH 7.4) in a v/v ratio of 
5/2/2/1 was prepared and added to each well (32 μL). Acetone (60 μL) was added to each 
well. The UV/vis absorbance was recorded on a SpectraMax P340 plate reader at 405 nm. 
Sigmoidal dose-response curves were obtained using the absorbance values on using 
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